BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601-609. [PMID: 23055155 DOI: 10.1002/hep.26093] [Cited by in Crossref: 769] [Cited by in F6Publishing: 668] [Article Influence: 96.1] [Reference Citation Analysis]
Number Citing Articles
1 Pham TP, Alou MT, Golden MH, Million M, Raoult D. Difference between kwashiorkor and marasmus: Comparative meta-analysis of pathogenic characteristics and implications for treatment. Microb Pathog 2021;150:104702. [PMID: 33359074 DOI: 10.1016/j.micpath.2020.104702] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Chen J, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int J Mol Sci 2020;21:E5214. [PMID: 32717871 DOI: 10.3390/ijms21155214] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
3 Sun YL, Li WQ, Ding PX, Wang ZW, Wei CH, Ma XX, Zhang RF, Wu Y, Zhou L, Liang RP, Zhang YP, Zhao YP, Zhu RT, Li J. Specific alterations in gut microbiota are associated with prognosis of Budd-Chiari syndrome. Oncotarget 2018;9:3303-20. [PMID: 29423048 DOI: 10.18632/oncotarget.23234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, Zhao X, Li N, Li S, Xue G, Cheng W, Li B, Li H, Lin W, Tian C, Zhao J, Han J, An D, Zhang Q, Wei H, Zheng M, Ma X, Li W, Chen X, Zhang Z, Zeng H, Ying S, Wu J, Yang R, Liu D. Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae. Cell Metab 2019; 30: 675-688. e7. [PMID: 31543403 DOI: 10.1016/j.cmet.2019.08.018] [Cited by in Crossref: 100] [Cited by in F6Publishing: 75] [Article Influence: 50.0] [Reference Citation Analysis]
5 Zhao Z, Wang B, Mu L, Wang H, Luo J, Yang Y, Yang H, Li M, Zhou L, Tao C. Long-Term Exposure to Ceftriaxone Sodium Induces Alteration of Gut Microbiota Accompanied by Abnormal Behaviors in Mice. Front Cell Infect Microbiol 2020;10:258. [PMID: 32714875 DOI: 10.3389/fcimb.2020.00258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
6 Gkolfakis P, Dimitriadis G, Triantafyllou K. Gut microbiota and non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2015;14:572-81. [PMID: 26663004 DOI: 10.1016/s1499-3872(15)60026-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 22] [Article Influence: 8.8] [Reference Citation Analysis]
7 Plaza-Díaz J, Solís-Urra P, Rodríguez-Rodríguez F, Olivares-Arancibia J, Navarro-Oliveros M, Abadía-Molina F, Álvarez-Mercado AI. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage. Int J Mol Sci 2020;21:E8351. [PMID: 33171747 DOI: 10.3390/ijms21218351] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
8 Reccia I, Kumar J, Akladios C, Virdis F, Pai M, Habib N, Spalding D. Non-alcoholic fatty liver disease: A sign of systemic disease. Metabolism. 2017;72:94-108. [PMID: 28641788 DOI: 10.1016/j.metabol.2017.04.011] [Cited by in Crossref: 85] [Cited by in F6Publishing: 70] [Article Influence: 21.3] [Reference Citation Analysis]
9 Liu HX, Rocha CS, Dandekar S, Wan YJ. Functional analysis of the relationship between intestinal microbiota and the expression of hepatic genes and pathways during the course of liver regeneration. J Hepatol 2016;64:641-50. [PMID: 26453969 DOI: 10.1016/j.jhep.2015.09.022] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 9.8] [Reference Citation Analysis]
10 Zouiouich S, Loftfield E, Huybrechts I, Viallon V, Louca P, Vogtmann E, Wells PM, Steves CJ, Herzig KH, Menni C, Jarvelin MR, Sinha R, Gunter MJ. Markers of metabolic health and gut microbiome diversity: findings from two population-based cohort studies. Diabetologia 2021;64:1749-59. [PMID: 34110438 DOI: 10.1007/s00125-021-05464-w] [Reference Citation Analysis]
11 Hrncir T, Hrncirova L, Kverka M, Hromadka R, Machova V, Trckova E, Kostovcikova K, Kralickova P, Krejsek J, Tlaskalova-Hogenova H. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. Microorganisms 2021;9:957. [PMID: 33946843 DOI: 10.3390/microorganisms9050957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Boursier J, Diehl AM. Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog. 2015;11:e1004559. [PMID: 25625278 DOI: 10.1371/journal.ppat.1004559] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 12.0] [Reference Citation Analysis]
13 Cui Y, Wang Q, Chang R, Zhou X, Xu C. Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota. J Agric Food Chem. 2019;67:2754-2762. [PMID: 30798598 DOI: 10.1021/acs.jafc.9b00080] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 20.5] [Reference Citation Analysis]
14 Takahashi H, Kotani K, Tanaka K, Egucih Y, Anzai K. Therapeutic Approaches to Nonalcoholic Fatty Liver Disease: Exercise Intervention and Related Mechanisms. Front Endocrinol (Lausanne). 2018;9:588. [PMID: 30374329 DOI: 10.3389/fendo.2018.00588] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
15 [DOI: 10.1101/2020.08.06.240655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Aktas B, De Wolfe TJ, Safdar N, Darien BJ, Steele JL. The Impact of Lactobacillus casei on the Composition of the Cecal Microbiota and Innate Immune System Is Strain Specific. PLoS One 2016;11:e0156374. [PMID: 27244133 DOI: 10.1371/journal.pone.0156374] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
17 Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R, Sikaroodi M, Lam V, Crotty P, Bailey J, Myers RP, Rioux KP. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11:868-75.e1-3. [PMID: 23454028 DOI: 10.1016/j.cgh.2013.02.015] [Cited by in Crossref: 360] [Cited by in F6Publishing: 316] [Article Influence: 45.0] [Reference Citation Analysis]
18 Boursier J, Diehl AM. Nonalcoholic Fatty Liver Disease and the Gut Microbiome. Clin Liver Dis 2016;20:263-75. [PMID: 27063268 DOI: 10.1016/j.cld.2015.10.012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 8.3] [Reference Citation Analysis]
19 Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab. 2016;5:782-794. [PMID: 27617201 DOI: 10.1016/j.molmet.2016.06.003] [Cited by in Crossref: 121] [Cited by in F6Publishing: 94] [Article Influence: 24.2] [Reference Citation Analysis]
20 Shen L, Ji H. Intestinal Microbiota and Metabolic Diseases: Pharmacological Implications. Trends in Pharmacological Sciences 2016;37:169-71. [DOI: 10.1016/j.tips.2015.11.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
21 Wang T, Huang S, Wu C, Wang N, Zhang R, Wang M, Mao D. Intestinal Microbiota and Liver Diseases: Insights into Therapeutic Use of Traditional Chinese Medicine. Evid Based Complement Alternat Med 2021;2021:6682581. [PMID: 33976705 DOI: 10.1155/2021/6682581] [Reference Citation Analysis]
22 Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72:558-577. [PMID: 31622696 DOI: 10.1016/j.jhep.2019.10.003] [Cited by in Crossref: 141] [Cited by in F6Publishing: 114] [Article Influence: 70.5] [Reference Citation Analysis]
23 Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic Fatty Liver Disease: A Clinical Update. J Clin Transl Hepatol. 2017;5:384-393. [PMID: 29226105 DOI: 10.14218/jcth.2017.00013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
24 Larsen JM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology. 2017;151:363-374. [PMID: 28542929 DOI: 10.1111/imm.12760] [Cited by in Crossref: 298] [Cited by in F6Publishing: 244] [Article Influence: 74.5] [Reference Citation Analysis]
25 Chopyk DM, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. Gastroenterology 2020;159:849-63. [PMID: 32569766 DOI: 10.1053/j.gastro.2020.04.077] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 22.0] [Reference Citation Analysis]
26 Issa D, Patel V, Sanyal AJ. Future therapy for non-alcoholic fatty liver disease. Liver Int 2018;38 Suppl 1:56-63. [PMID: 29427492 DOI: 10.1111/liv.13676] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
27 Hartmann P, Schnabl B. Risk factors for progression of and treatment options for NAFLD in children. Clin Liver Dis (Hoboken) 2018;11:11-5. [PMID: 29629177 DOI: 10.1002/cld.685] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
28 Stanislawski MA, Lozupone CA, Wagner BD, Eggesbø M, Sontag MK, Nusbacher NM, Martinez M, Dabelea D. Gut microbiota in adolescents and the association with fatty liver: the EPOCH study. Pediatr Res 2018;84:219-27. [PMID: 29538359 DOI: 10.1038/pr.2018.32] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
29 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients. 2014;6:5583-5599. [PMID: 25479248 DOI: 10.3390/nu6125583] [Cited by in Crossref: 56] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
30 Lyu Y, Wu L, Wang F, Shen X, Lin D. Carotenoid supplementation and retinoic acid in immunoglobulin A regulation of the gut microbiota dysbiosis. Exp Biol Med (Maywood) 2018;243:613-20. [PMID: 29534601 DOI: 10.1177/1535370218763760] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 12.7] [Reference Citation Analysis]
31 Iruzubieta P, Medina JM, Fernández-López R, Crespo J, de la Cruz F. A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. J Clin Med 2020;9:E1369. [PMID: 32392712 DOI: 10.3390/jcm9051369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
32 Yang M, Gong S, Ye SQ, Lyman B, Geng L, Chen P, Li DY. Non-alcoholic fatty liver disease in children: focus on nutritional interventions. Nutrients 2014;6:4691-705. [PMID: 25353664 DOI: 10.3390/nu6114691] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
33 Caussy C, Loomba R. Gut microbiome, microbial metabolites and the development of NAFLD. Nat Rev Gastroenterol Hepatol 2018;15:719-20. [PMID: 30158571 DOI: 10.1038/s41575-018-0058-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
34 Benhammou JN, Lin J, Hussain SK, El-Kabany M. Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. Hepatoma Res 2020;6:35. [PMID: 32685690 DOI: 10.20517/2394-5079.2020.16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
35 Yang G, Wei J, Liu P, Zhang Q, Tian Y, Hou G, Meng L, Xin Y, Jiang X. Role of the gut microbiota in type 2 diabetes and related diseases. Metabolism 2021;117:154712. [PMID: 33497712 DOI: 10.1016/j.metabol.2021.154712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
36 Menon R, Ramanan V, Korolev KS. Interactions between species introduce spurious associations in microbiome studies. PLoS Comput Biol 2018;14:e1005939. [PMID: 29338008 DOI: 10.1371/journal.pcbi.1005939] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
37 Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. World J Hepatol. 2017;9:533-543. [PMID: 28469809 DOI: 10.4254/wjh.v9.i11.533] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 19.0] [Reference Citation Analysis]
38 Astbury S, Atallah E, Vijay A, Aithal GP, Grove JI, Valdes AM. Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. Gut Microbes 2020;11:569-80. [PMID: 31696774 DOI: 10.1080/19490976.2019.1681861] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
39 Ling Z, Liu X, Cheng Y, Yan X, Wu S. Gut microbiota and aging. Crit Rev Food Sci Nutr 2020;:1-56. [PMID: 33377391 DOI: 10.1080/10408398.2020.1867054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276-1285. [PMID: 24738701 DOI: 10.1111/apt.12758] [Cited by in Crossref: 232] [Cited by in F6Publishing: 186] [Article Influence: 33.1] [Reference Citation Analysis]
41 Cani PD. When specific gut microbes reveal a possible link between hepatic steatosis and adipose tissue. J Hepatol 2014;61:5-6. [PMID: 24727121 DOI: 10.1016/j.jhep.2014.04.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
42 Jonscher KR, Bruce KD. Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions. Adv Exp Med Biol 2019;1134:33-58. [PMID: 30919331 DOI: 10.1007/978-3-030-12668-1_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Scotti E, Boué S, Sasso GL, Zanetti F, Belcastro V, Poussin C, Sierro N, Battey J, Gimalac A, Ivanov NV, Hoeng J. Exploring the microbiome in health and disease: Implications for toxicology. Toxicology Research and Application 2017;1:239784731774188. [DOI: 10.1177/2397847317741884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
44 Kishida Y, Okubo H, Ohno H, Oki K, Yoneda M. Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model. J Gastroenterol. 2017;52:1180-1191. [PMID: 28349245 DOI: 10.1007/s00535-017-1331-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
45 Ajmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? Hepatology. 2017;65:2090-2099. [PMID: 28100008 DOI: 10.1002/hep.29055] [Cited by in Crossref: 68] [Cited by in F6Publishing: 49] [Article Influence: 17.0] [Reference Citation Analysis]
46 Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019;68:1516-1526. [PMID: 31076401 DOI: 10.1136/gutjnl-2019-318427] [Cited by in Crossref: 151] [Cited by in F6Publishing: 120] [Article Influence: 75.5] [Reference Citation Analysis]
47 Ponziani FR, Picca A, Marzetti E, Calvani R, Conta G, Del Chierico F, Capuani G, Faccia M, Fianchi F, Funaro B, Josè Coelho-Junior H, Petito V, Rinninella E, Paroni Sterbini F, Reddel S, Vernocchi P, Cristina Mele M, Miccheli A, Putignani L, Sanguinetti M, Pompili M, Gasbarrini A; GuLiver study group. Characterization of the gut-liver-muscle axis in cirrhotic patients with sarcopenia. Liver Int 2021;41:1320-34. [PMID: 33713524 DOI: 10.1111/liv.14876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
48 Zhao Y, Zhou J, Liu J, Wang Z, Chen M, Zhou S. Metagenome of Gut Microbiota of Children With Nonalcoholic Fatty Liver Disease. Front Pediatr 2019;7:518. [PMID: 31921729 DOI: 10.3389/fped.2019.00518] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
49 Ko JS. New Perspectives in Pediatric Nonalcoholic Fatty Liver Disease: Epidemiology, Genetics, Diagnosis, and Natural History. Pediatr Gastroenterol Hepatol Nutr 2019;22:501-10. [PMID: 31777715 DOI: 10.5223/pghn.2019.22.6.501] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
50 Bo T, Shao S, Wu D, Niu S, Zhao J, Gao L. Relative variations of gut microbiota in disordered cholesterol metabolism caused by high-cholesterol diet and host genetics. Microbiologyopen 2017;6. [PMID: 28660729 DOI: 10.1002/mbo3.491] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
51 Goel A, Gupta M, Aggarwal R. Gut microbiota and liver disease. J Gastroenterol Hepatol 2014;29:1139-48. [PMID: 24547986 DOI: 10.1111/jgh.12556] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 9.1] [Reference Citation Analysis]
52 Bluemel S, Wang L, Martino C, Lee S, Wang Y, Williams B, Horvath A, Stadlbauer V, Zengler K, Schnabl B. The Role of Intestinal C-type Regenerating Islet Derived-3 Lectins for Nonalcoholic Steatohepatitis. Hepatol Commun 2018;2:393-406. [PMID: 29619418 DOI: 10.1002/hep4.1165] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
53 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
54 Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1798-1810. [PMID: 27003600 DOI: 10.1053/j.gastro.2016.03.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 13.8] [Reference Citation Analysis]
55 Goto M, Azuma K, Arima H, Kaneko S, Higashi T, Motoyama K, Michihara A, Shimizu T, Kadowaki D, Maruyama T, Otagiri M, Iohara D, Hirayama F, Anraku M. Sacran, a sulfated polysaccharide, suppresses the absorption of lipids and modulates the intestinal flora in non-alcoholic steatohepatitis model rats. Life Sci 2021;268:118991. [PMID: 33417955 DOI: 10.1016/j.lfs.2020.118991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Ren Z, Jiang J, Xie H, Li A, Lu H, Xu S, Zhou L, Zhang H, Cui G, Chen X, Liu Y, Wu L, Qin N, Sun R, Wang W, Li L, Zheng S. Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China. Oncotarget. 2017;8:95176-95191. [PMID: 29221120 DOI: 10.18632/oncotarget.18820] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 14.3] [Reference Citation Analysis]
57 Liu JP, Zou WL, Chen SJ, Wei HY, Yin YN, Zou YY, Lu FG. Effects of different diets on intestinal microbiota and nonalcoholic fatty liver disease development. World J Gastroenterol. 2016;22:7353-7364. [PMID: 27621581 DOI: 10.3748/wjg.v22.i32.7353] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
58 Duarte SMB, Stefano JT, Oliveira CP. Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Ann Hepatol 2019;18:416-21. [PMID: 31036494 DOI: 10.1016/j.aohep.2019.04.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
59 Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. Diseases 2019;7:E27. [PMID: 30823570 DOI: 10.3390/diseases7010027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
60 Li F, Ye J, Shao C, Zhong B. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis. Lipids Health Dis 2021;20:22. [PMID: 33637088 DOI: 10.1186/s12944-021-01440-w] [Reference Citation Analysis]
61 Tilg H, Adolph TE, Moschen AR. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology. 2021;73:833-842. [PMID: 32780879 DOI: 10.1002/hep.31518] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 35.0] [Reference Citation Analysis]
62 Baffy G. Potential mechanisms linking gut microbiota and portal hypertension. Liver Int. 2019;39:598-609. [PMID: 30312513 DOI: 10.1111/liv.13986] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
63 Harvie R, Walmsley R, Schultz M; New Zealand Society of Gastroenterology. "We are what our bacteria eat": The role of bacteria in personalizing nutrition therapy in gastrointestinal conditions. J Gastroenterol Hepatol 2017;32:352-7. [PMID: 27248703 DOI: 10.1111/jgh.13462] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
64 Seymour KA, Abdelmalek MF. The role of bariatric surgery in the management of nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2021;37:208-15. [PMID: 33769376 DOI: 10.1097/MOG.0000000000000721] [Reference Citation Analysis]
65 Mokhtari Z, Gibson DL, Hekmatdoost A. Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. Adv Nutr 2017;8:240-52. [PMID: 28298269 DOI: 10.3945/an.116.013151] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 17.5] [Reference Citation Analysis]
66 Inamine T, Schnabl B. Immunoglobulin A and liver diseases. J Gastroenterol 2018;53:691-700. [PMID: 29075899 DOI: 10.1007/s00535-017-1400-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
67 Ussar S, Griffin NW, Bezy O, Fujisaka S, Vienberg S, Softic S, Deng L, Bry L, Gordon JI, Kahn CR. Interactions between Gut Microbiota, Host Genetics and Diet Modulate the Predisposition to Obesity and Metabolic Syndrome. Cell Metab 2015;22:516-30. [PMID: 26299453 DOI: 10.1016/j.cmet.2015.07.007] [Cited by in Crossref: 293] [Cited by in F6Publishing: 262] [Article Influence: 48.8] [Reference Citation Analysis]
68 Kang Y, Zhang X, Cai Y, Su J, Kong X. Gut microbiota and metabolic disease: from pathogenesis to new therapeutic strategies. Reviews in Medical Microbiology 2016;27:141-52. [DOI: 10.1097/mrm.0000000000000085] [Cited by in Crossref: 11] [Article Influence: 2.2] [Reference Citation Analysis]
69 Derovs A, Laivacuma S, Krumina A. Targeting Microbiota: What Do We Know about It at Present? Medicina (Kaunas) 2019;55:E459. [PMID: 31405111 DOI: 10.3390/medicina55080459] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
70 Rizzatti G, Lopetuso LR, Gibiino G, Binda C, Gasbarrini A. Proteobacteria: A Common Factor in Human Diseases. Biomed Res Int. 2017;2017:9351507. [PMID: 29230419 DOI: 10.1155/2017/9351507] [Cited by in Crossref: 239] [Cited by in F6Publishing: 188] [Article Influence: 59.8] [Reference Citation Analysis]
71 Liu W, Zhao S, Wang J, Shi J, Sun Y, Wang W, Ning G, Hong J, Liu R. Grape seed proanthocyanidin extract ameliorates inflammation and adiposity by modulating gut microbiota in high-fat diet mice. Mol Nutr Food Res 2017;61. [PMID: 28500724 DOI: 10.1002/mnfr.201601082] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 14.5] [Reference Citation Analysis]
72 Croci S, D'Apolito LI, Gasperi V, Catani MV, Savini I. Dietary Strategies for Management of Metabolic Syndrome: Role of Gut Microbiota Metabolites. Nutrients 2021;13:1389. [PMID: 33919016 DOI: 10.3390/nu13051389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
73 Boland ML, Oró D, Tølbøl KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE, Fernandes F, Tovchigrechko A, Veidal SS, Warrener P, Sellman BR, Jelsing J, Feigh M, Vrang N, Trevaskis JL, Hansen HH. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J Gastroenterol 2019;25:4904-20. [PMID: 31543682 DOI: 10.3748/wjg.v25.i33.4904] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
74 Moran-Ramos S, López-Contreras BE, Canizales-Quinteros S. Gut Microbiota in Obesity and Metabolic Abnormalities: A Matter of Composition or Functionality? Arch Med Res 2017;48:735-53. [PMID: 29292011 DOI: 10.1016/j.arcmed.2017.11.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
75 Nishitsuji K, Watanabe S, Xiao J, Nagatomo R, Ogawa H, Tsunematsu T, Umemoto H, Morimoto Y, Akatsu H, Inoue K, Tsuneyama K. Effect of coffee or coffee components on gut microbiome and short-chain fatty acids in a mouse model of metabolic syndrome. Sci Rep. 2018;8:16173. [PMID: 30385796 DOI: 10.1038/s41598-018-34571-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
76 Shin NR, Whon TW, Bae JW. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015;33:496-503. [PMID: 26210164 DOI: 10.1016/j.tibtech.2015.06.011] [Cited by in Crossref: 959] [Cited by in F6Publishing: 789] [Article Influence: 159.8] [Reference Citation Analysis]
77 Liu M, Xie W, Wan X, Deng T. Clostridium butyricum modulates gut microbiota and reduces colitis associated colon cancer in mice. Int Immunopharmacol 2020;88:106862. [PMID: 32771947 DOI: 10.1016/j.intimp.2020.106862] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
78 Liu Z, Wang X, Ou S, Arowolo MA, Hou DX, He J. Effects of Achyranthes bidentata Polysaccharides on Intestinal Morphology, Immune Response, and Gut Microbiome in Yellow Broiler Chickens Challenged with Escherichia coli K88. Polymers (Basel) 2018;10:E1233. [PMID: 30961158 DOI: 10.3390/polym10111233] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
79 Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019;13:193-204. [PMID: 30791767 DOI: 10.1080/17474124.2019.1569513] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
80 Winnier DA, Fourcaudot M, Norton L, Abdul-Ghani MA, Hu SL, Farook VS, Coletta DK, Kumar S, Puppala S, Chittoor G, Dyer TD, Arya R, Carless M, Lehman DM, Curran JE, Cromack DT, Tripathy D, Blangero J, Duggirala R, Göring HH, DeFronzo RA, Jenkinson CP. Transcriptomic identification of ADH1B as a novel candidate gene for obesity and insulin resistance in human adipose tissue in Mexican Americans from the Veterans Administration Genetic Epidemiology Study (VAGES). PLoS One 2015;10:e0119941. [PMID: 25830378 DOI: 10.1371/journal.pone.0119941] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
81 Wu X, Unno T, Kang S, Park S. A Korean-Style Balanced Diet Has a Potential Connection with Ruminococcaceae Enterotype and Reduction of Metabolic Syndrome Incidence in Korean Adults. Nutrients 2021;13:495. [PMID: 33546299 DOI: 10.3390/nu13020495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
82 Agosti P, Sabbà C, Mazzocca A. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:607-17. [DOI: 10.1016/j.bbadis.2017.11.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
83 Li R, Yao Y, Gao P, Bu S. The Therapeutic Efficacy of Curcumin vs. Metformin in Modulating the Gut Microbiota in NAFLD Rats: A Comparative Study. Front Microbiol 2020;11:555293. [PMID: 33584555 DOI: 10.3389/fmicb.2020.555293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Peiseler M, Tacke F. Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma. Cancers (Basel) 2021;13:730. [PMID: 33578800 DOI: 10.3390/cancers13040730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018;47:192-202. [PMID: 29083037 DOI: 10.1111/apt.14397] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 19.5] [Reference Citation Analysis]
86 Mandala A, Janssen RC, Palle S, Short KR, Friedman JE. Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms. Nutrients 2020;12:E3166. [PMID: 33081177 DOI: 10.3390/nu12103166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
87 Nobili V, Mosca A, Alterio T, Cardile S, Putignani L. Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT). In: Guandalini S, Indrio F, editors. Probiotics and Child Gastrointestinal Health. Cham: Springer International Publishing; 2019. pp. 85-100. [DOI: 10.1007/5584_2018_318] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
88 Bibbò S, Ianiro G, Dore MP, Simonelli C, Newton EE, Cammarota G. Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease. Mediators Inflamm 2018;2018:9321643. [PMID: 29563854 DOI: 10.1155/2018/9321643] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 6.7] [Reference Citation Analysis]
89 Panasevich MR, Schuster CM, Phillips KE, Meers GM, Chintapalli SV, Wankhade UD, Shankar K, Butteiger DN, Krul ES, Thyfault JP, Rector RS. Soy compared with milk protein in a Western diet changes fecal microbiota and decreases hepatic steatosis in obese OLETF rats. J Nutr Biochem 2017;46:125-36. [PMID: 28605664 DOI: 10.1016/j.jnutbio.2017.05.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
90 Costea PI, Hildebrand F, Arumugam M, Bäckhed F, Blaser MJ, Bushman FD, de Vos WM, Ehrlich SD, Fraser CM, Hattori M, Huttenhower C, Jeffery IB, Knights D, Lewis JD, Ley RE, Ochman H, O'Toole PW, Quince C, Relman DA, Shanahan F, Sunagawa S, Wang J, Weinstock GM, Wu GD, Zeller G, Zhao L, Raes J, Knight R, Bork P. Enterotypes in the landscape of gut microbial community composition. Nat Microbiol 2018;3:8-16. [PMID: 29255284 DOI: 10.1038/s41564-017-0072-8] [Cited by in Crossref: 320] [Cited by in F6Publishing: 244] [Article Influence: 80.0] [Reference Citation Analysis]
91 Li F, Sun G, Wang Z, Wu W, Guo H, Peng L, Wu L, Guo X, Yang Y. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients. Sci China Life Sci 2018;61:770-8. [PMID: 29948900 DOI: 10.1007/s11427-017-9303-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
92 Rahman K, Desai C, Iyer SS, Thorn NE, Kumar P, Liu Y, Smith T, Neish AS, Li H, Tan S, Wu P, Liu X, Yu Y, Farris AB, Nusrat A, Parkos CA, Anania FA. Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. Gastroenterology. 2016;151:733-746.e12. [PMID: 27342212 DOI: 10.1053/j.gastro.2016.06.022] [Cited by in Crossref: 127] [Cited by in F6Publishing: 109] [Article Influence: 25.4] [Reference Citation Analysis]
93 Rau M, Rehman A, Dittrich M, Groen AK, Hermanns HM, Seyfried F, Beyersdorf N, Dandekar T, Rosenstiel P, Geier A. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European Gastroenterol J. 2018;6:1496-1507. [PMID: 30574320 DOI: 10.1177/2050640618804444] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 18.0] [Reference Citation Analysis]
94 Arumugam MK, Paal MC, Donohue TM Jr, Ganesan M, Osna NA, Kharbanda KK. Beneficial Effects of Betaine: A Comprehensive Review. Biology (Basel) 2021;10:456. [PMID: 34067313 DOI: 10.3390/biology10060456] [Reference Citation Analysis]
95 Imai J, Kitamoto S, Kamada N. The pathogenic oral-gut-liver axis: new understandings and clinical implications. Expert Rev Clin Immunol 2021;17:727-36. [PMID: 34057877 DOI: 10.1080/1744666X.2021.1935877] [Reference Citation Analysis]
96 Krishnan S, Ding Y, Saedi N, Choi M, Sridharan GV, Sherr DH, Yarmush ML, Alaniz RC, Jayaraman A, Lee K. Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. Cell Rep. 2018;23:1099-1111. [PMID: 29694888 DOI: 10.1016/j.celrep.2018.03.109] [Cited by in Crossref: 160] [Cited by in F6Publishing: 129] [Article Influence: 80.0] [Reference Citation Analysis]
97 Lang S, Schnabl B. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future. Cell Host Microbe 2020;28:233-44. [PMID: 32791115 DOI: 10.1016/j.chom.2020.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 20.0] [Reference Citation Analysis]
98 Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, Urquhart B, Harvie R, Mckenzie C, Summers K, Reid G, Burton JP, Silverman M. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. Am J Gastroenterol 2020;115:1055-65. [DOI: 10.14309/ajg.0000000000000661] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 37.0] [Reference Citation Analysis]
99 Ni Y, Ni L, Zhuge F, Fu Z. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2020;64:e2000375. [PMID: 32738185 DOI: 10.1002/mnfr.202000375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
100 Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764-775. [PMID: 26600078 DOI: 10.1002/hep.28356 doi: 10.1002/hep.28356] [Reference Citation Analysis]
101 du Plessis J, Korf H, van Pelt J, Windmolders P, Vander Elst I, Verrijken A, Hubens G, Van Gaal L, Cassiman D, Nevens F, Francque S, van der Merwe S. Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD. PLoS One 2016;11:e0166048. [PMID: 27992443 DOI: 10.1371/journal.pone.0166048] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
102 Augustyn M, Grys I, Kukla M. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease. Clin Exp Hepatol. 2019;5:1-10. [PMID: 30915401 DOI: 10.5114/ceh.2019.83151] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
103 Fukui H. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? Diseases. 2019;7. [PMID: 31726747 DOI: 10.3390/diseases7040058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 15.5] [Reference Citation Analysis]
104 Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 2021;19:55-71. [PMID: 32887946 DOI: 10.1038/s41579-020-0433-9] [Cited by in Crossref: 125] [Cited by in F6Publishing: 79] [Article Influence: 125.0] [Reference Citation Analysis]
105 Tsai MC, Liu YY, Lin CC, Wang CC, Wu YJ, Yong CC, Chen KD, Chuah SK, Yao CC, Huang PY, Chen CH, Hu TH, Chen CL. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan. Nutrients 2020;12:E820. [PMID: 32204538 DOI: 10.3390/nu12030820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
106 Zhou Y, Xu H, Huang H, Li Y, Chen H, He J, Du Y, Chen Y, Zhou Y, Nie Y. Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders? Biomed Res Int. 2019;2019:3469754. [PMID: 31467881 DOI: 10.1155/2019/3469754] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
107 Ahlawat S, Asha, Sharma KK. Gut-organ axis: a microbial outreach and networking. Lett Appl Microbiol 2021;72:636-68. [PMID: 32472555 DOI: 10.1111/lam.13333] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 19.0] [Reference Citation Analysis]
108 Chen D, Le TH, Shahidipour H, Read SA, Ahlenstiel G. The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression. Cells 2019;8:E1324. [PMID: 31717860 DOI: 10.3390/cells8111324] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
109 Schwenger KJ, Clermont-Dejean N, Allard JP. The role of the gut microbiome in chronic liver disease: the clinical evidence revised. JHEP Rep 2019;1:214-26. [PMID: 32039372 DOI: 10.1016/j.jhepr.2019.04.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 14.5] [Reference Citation Analysis]
110 Del Chierico F, Nobili V, Vernocchi P, Russo A, De Stefanis C, Gnani D, Furlanello C, Zandonà A, Paci P, Capuani G, Dallapiccola B, Miccheli A, Alisi A, Putignani L. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta‐omics‐based approach. Hepatology 2016;65:451-64. [DOI: 10.1002/hep.28572] [Cited by in Crossref: 282] [Cited by in F6Publishing: 253] [Article Influence: 56.4] [Reference Citation Analysis]
111 Anand G, Zarrinpar A, Loomba R. Targeting Dysbiosis for the Treatment of Liver Disease. Semin Liver Dis. 2016;36:37-47. [PMID: 26870931 DOI: 10.1055/s-0035-1571276] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
112 Nishitsuji K, Xiao J, Nagatomo R, Umemoto H, Morimoto Y, Akatsu H, Inoue K, Tsuneyama K. Analysis of the gut microbiome and plasma short-chain fatty acid profiles in a spontaneous mouse model of metabolic syndrome. Sci Rep 2017;7:15876. [PMID: 29158587 DOI: 10.1038/s41598-017-16189-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
113 Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P, Diehl AM. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016;63:764-75. [PMID: 26600078 DOI: 10.1002/hep.28356] [Cited by in Crossref: 512] [Cited by in F6Publishing: 445] [Article Influence: 102.4] [Reference Citation Analysis]
114 Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68:280-295. [PMID: 29154964 DOI: 10.1016/j.jhep.2017.11.014] [Cited by in Crossref: 257] [Cited by in F6Publishing: 219] [Article Influence: 64.3] [Reference Citation Analysis]
115 Kwong EK, Puri P. Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease. Transl Gastroenterol Hepatol 2021;6:3. [PMID: 33409398 DOI: 10.21037/tgh.2020.02.18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
116 Tokuhara D. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents. Front Nutr 2021;8:700058. [PMID: 34250000 DOI: 10.3389/fnut.2021.700058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Sharpton SR, Ajmera V, Loomba R. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clin Gastroenterol Hepatol 2019;17:296-306. [PMID: 30196156 DOI: 10.1016/j.cgh.2018.08.065] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 20.7] [Reference Citation Analysis]
118 Zheng R, Wang G, Pang Z, Ran N, Gu Y, Guan X, Yuan Y, Zuo X, Pan H, Zheng J, Wang F. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma. Cancer Med 2020;9:4232-50. [PMID: 32281295 DOI: 10.1002/cam4.3045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
119 Liu X, Mao B, Gu J, Wu J, Cui S, Wang G, Zhao J, Zhang H, Chen W. Blautia-a new functional genus with potential probiotic properties? Gut Microbes 2021;13:1-21. [PMID: 33525961 DOI: 10.1080/19490976.2021.1875796] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
120 Ahn SB, Jun DW, Kang BK, Lim JH, Lim S, Chung MJ. Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep. 2019;9:5688. [PMID: 30952918 DOI: 10.1038/s41598-019-42059-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 17.5] [Reference Citation Analysis]
121 Mencin AA, Loomba R, Lavine JE. Caring for children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol 2015;12:617-28. [PMID: 26323878 DOI: 10.1038/nrgastro.2015.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
122 Iwaki M, Kessoku T, Ozaki A, Kasai Y, Kobayashi T, Nogami A, Honda Y, Ogawa Y, Imajo K, Yoneda M, Maeda A, Tanaka Y, Nakajima S, Ohno H, Usuda H, Kawanaka M, Kawaguchi T, Torimura T, Kage M, Hyogo H, Takahashi H, Eguchi Y, Aishima S, Wada K, Kobayashi N, Sumida Y, Saito S, Nakajima A. Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2021;36:2275-84. [PMID: 33709477 DOI: 10.1111/jgh.15487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
123 Lequoy M, Gigante E, Couty JP, Desbois-Mouthon C. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms. Horm Mol Biol Clin Investig 2020;41:/j/hmbci. [PMID: 32112699 DOI: 10.1515/hmbci-2019-0044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
124 Zhou R, Fan X, Schnabl B. Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. Transl Res 2019;209:22-38. [PMID: 30853445 DOI: 10.1016/j.trsl.2019.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
125 Iwao M, Gotoh K, Arakawa M, Endo M, Honda K, Seike M, Murakami K, Shibata H. Supplementation of branched-chain amino acids decreases fat accumulation in the liver through intestinal microbiota-mediated production of acetic acid. Sci Rep. 2020;10:18768. [PMID: 33127939 DOI: 10.1038/s41598-020-75542-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
126 Monnoyer R, Haugum K, Lautridou J, Flatberg A, Hjelde A, Eftedal I. Shifts in the Oral Microbiota During a Four-Week Commercial Saturation Dive to 200 Meters. Front Physiol 2021;12:669355. [PMID: 33986696 DOI: 10.3389/fphys.2021.669355] [Reference Citation Analysis]
127 Hegazy MA, Mogawer SM, Alnaggar ARLR, Ghoniem OA, Abdel Samie RM. Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH. Diabetes Metab Syndr Obes 2020;13:3861-72. [PMID: 33116732 DOI: 10.2147/DMSO.S249949] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
128 Munukka E, Ahtiainen JP, Puigbó P, Jalkanen S, Pahkala K, Keskitalo A, Kujala UM, Pietilä S, Hollmén M, Elo L, Huovinen P, D'Auria G, Pekkala S. Six-Week Endurance Exercise Alters Gut Metagenome That Is not Reflected in Systemic Metabolism in Over-weight Women. Front Microbiol 2018;9:2323. [PMID: 30337914 DOI: 10.3389/fmicb.2018.02323] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 19.0] [Reference Citation Analysis]
129 Nicoletti A, Ponziani FR, Biolato M, Valenza V, Marrone G, Sganga G, Gasbarrini A, Miele L, Grieco A. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World J Gastroenterol 2019;25:4814-34. [PMID: 31543676 DOI: 10.3748/wjg.v25.i33.4814] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 22] [Article Influence: 26.0] [Reference Citation Analysis]
130 Gallego-Durán R, Ampuero J, Funuyet J, Romero-Gómez M. [Alcoholic and non-alcoholic steatohepatitis: who is affected and what can we do for them?]. Gastroenterol Hepatol. 2013;36:587-596. [PMID: 24011648 DOI: 10.1016/j.gastrohep.2013.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
131 Barretto SA, Lasserre F, Huillet M, Régnier M, Polizzi A, Lippi Y, Fougerat A, Person E, Bruel S, Bétoulières C, Naylies C, Lukowicz C, Smati S, Guzylack L, Olier M, Théodorou V, Mselli-Lakhal L, Zalko D, Wahli W, Loiseau N, Gamet-Payrastre L, Guillou H, Ellero-Simatos S. The pregnane X receptor drives sexually dimorphic hepatic changes in lipid and xenobiotic metabolism in response to gut microbiota in mice. Microbiome 2021;9:93. [PMID: 33879258 DOI: 10.1186/s40168-021-01050-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Chow MD, Lee YH, Guo GL. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med. 2017;56:34-44. [PMID: 28442273 DOI: 10.1016/j.mam.2017.04.004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 13.3] [Reference Citation Analysis]
133 Ghoshal UC, Goel A, Quigley EMM. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm. Indian J Gastroenterol 2020;39:9-21. [PMID: 32291578 DOI: 10.1007/s12664-020-01027-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
134 Caligiuri A, Gentilini A, Marra F. Molecular Pathogenesis of NASH. Int J Mol Sci. 2016;17. [PMID: 27657051 DOI: 10.3390/ijms17091575] [Cited by in Crossref: 79] [Cited by in F6Publishing: 62] [Article Influence: 15.8] [Reference Citation Analysis]
135 Qin T, Fu J, Verkade HJ. The role of the gut microbiome in graft fibrosis after pediatric liver transplantation. Hum Genet 2021;140:709-24. [PMID: 32920649 DOI: 10.1007/s00439-020-02221-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Derra A, Bator M, Menżyk T, Kukla M. Underrated enemy - from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract. Clin Exp Hepatol 2018;4:55-71. [PMID: 29904722 DOI: 10.5114/ceh.2018.75955] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
137 Flass T, Tong S, Frank DN, Wagner BD, Robertson CE, Kotter CV, Sokol RJ, Zemanick E, Accurso F, Hoffenberg EJ, Narkewicz MR. Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis. PLoS One 2015;10:e0116967. [PMID: 25658710 DOI: 10.1371/journal.pone.0116967] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
138 Huang W, Kong D. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD. Biomedicine & Pharmacotherapy 2021;135:111235. [DOI: 10.1016/j.biopha.2021.111235] [Reference Citation Analysis]
139 de Medeiros IC, de Lima JG. Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease? – A mechanistic hypothesis. Medical Hypotheses 2015;85:148-52. [DOI: 10.1016/j.mehy.2015.04.021] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
140 Nakamoto N, Schnabl B. Does the Intestinal Microbiota Explain Differences in the Epidemiology of Liver Disease between East and West? Inflamm Intest Dis. 2016;1:3-8. [PMID: 27243019 DOI: 10.1159/000443196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
141 Drescher HK, Schippers A, Clahsen T, Sahin H, Noels H, Hornef M, Wagner N, Trautwein C, Streetz KL, Kroy DC. β 7 -Integrin and MAdCAM-1 play opposing roles during the development of non-alcoholic steatohepatitis. Journal of Hepatology 2017;66:1251-64. [DOI: 10.1016/j.jhep.2017.02.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
142 Bakhshimoghaddam F, Alizadeh M. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. Clin Nutr ESPEN 2021;44:61-8. [PMID: 34330514 DOI: 10.1016/j.clnesp.2021.05.012] [Reference Citation Analysis]
143 Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28 Suppl 1:68-76. [PMID: 23855299 DOI: 10.1111/jgh.12212] [Cited by in Crossref: 148] [Cited by in F6Publishing: 127] [Article Influence: 21.1] [Reference Citation Analysis]
144 Svegliati-Baroni G, Patrício B, Lioci G, Macedo MP, Gastaldelli A. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. Int J Mol Sci 2020;21:E5820. [PMID: 32823659 DOI: 10.3390/ijms21165820] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
145 Goldner D, Lavine JE. Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges. Gastroenterology. 2020;158:1967-1983.e1. [PMID: 32201176 DOI: 10.1053/j.gastro.2020.01.048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 19.0] [Reference Citation Analysis]
146 Salzman NH, Schwimmer JB. Pediatric nonalcoholic fatty liver disease and the microbiome: Mechanisms contributing to pathogenesis and progression. Curr Opin Endocr Metab Res 2021;19:22-9. [PMID: 34222711 DOI: 10.1016/j.coemr.2021.05.003] [Reference Citation Analysis]
147 Ceccarani C, Bassanini G, Montanari C, Casiraghi MC, Ottaviano E, Morace G, Biasucci G, Paci S, Borghi E, Verduci E. Proteobacteria Overgrowth and Butyrate-Producing Taxa Depletion in the Gut Microbiota of Glycogen Storage Disease Type 1 Patients. Metabolites 2020;10:E133. [PMID: 32235604 DOI: 10.3390/metabo10040133] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
148 Beule AG. [The Microbiome - The Unscheduled Parameter for Future Therapies]. Laryngorhinootologie 2018;97:S279-311. [PMID: 29905360 DOI: 10.1055/s-0043-122301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
149 Betrapally NS, Gillevet PM, Bajaj JS. Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects? Gastroenterology 2016;150:1745-1755.e3. [PMID: 26948887 DOI: 10.1053/j.gastro.2016.02.073] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 14.6] [Reference Citation Analysis]
150 Wu YN, Zhang L, Chen T, Li X, He LH, Liu GX. Granulocyte-macrophage colony-stimulating factor protects mice against hepatocellular carcinoma by ameliorating intestinal dysbiosis and attenuating inflammation. World J Gastroenterol 2020;26:5420-36. [PMID: 33024394 DOI: 10.3748/wjg.v26.i36.5420] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol 2016;311:G1018-36. [PMID: 27686615 DOI: 10.1152/ajpgi.00245.2016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 9.2] [Reference Citation Analysis]
152 Cassard AM, Gérard P, Perlemuter G. Microbiota, Liver Diseases, and Alcohol. Microbiol Spectr 2017;5. [PMID: 28840806 DOI: 10.1128/microbiolspec.BAD-0007-2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
153 Aragonès G, González-García S, Aguilar C, Richart C, Auguet T. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:8507583. [PMID: 30719448 DOI: 10.1155/2019/8507583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
154 Delarue J, Lallès J. Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA. Mol Nutr Food Res 2016;60:147-59. [DOI: 10.1002/mnfr.201500346] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
155 Kennedy L, Francis H, Alpini G. Fructose Promotion of Intestinal and Liver Injury: A Sugar by Any Other Name That Isn't So Sweet. Hepatology 2021;73:2092-4. [PMID: 31273795 DOI: 10.1002/hep.30843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
156 Brenner DA, Paik YH, Schnabl B. Role of Gut Microbiota in Liver Disease.J Clin Gastroenterol. 2015;49 Suppl 1:S25-S27. [PMID: 26447960 DOI: 10.1097/MCG.0000000000000391] [Cited by in Crossref: 59] [Cited by in F6Publishing: 24] [Article Influence: 11.8] [Reference Citation Analysis]
157 Xanthakos SA, Crimmins NA, Chernausek SD. Abnormalities in the growth hormone axis and risk of nonalcoholic steatohepatitis: active player or innocent bystander? J Pediatr 2014;165:12-4. [PMID: 24793205 DOI: 10.1016/j.jpeds.2014.03.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
158 Qin DM, Wang XB, Zou N, Han C, Xu J. Gas Chromatography-Mass Spectrometry (GC-MS) Analysis of the Volatile Oil of Cichorium Glandulosum Boiss et Huet and its Effects on Carbon Tetrachloride-Induced Liver Fibrosis in Rats. Med Sci Monit 2019;25:3591-604. [PMID: 31089070 DOI: 10.12659/MSM.913445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
159 Song M, Li X, Zhang X, Shi H, Vos MB, Wei X, Wang Y, Gao H, Rouchka EC, Yin X, Zhou Z, Prough RA, Cave MC, McClain CJ. Dietary copper-fructose interactions alter gut microbial activity in male rats. Am J Physiol Gastrointest Liver Physiol 2018;314:G119-30. [PMID: 29025734 DOI: 10.1152/ajpgi.00378.2016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
160 Rodríguez-Carrio J, López P, Sánchez B, González S, Gueimonde M, Margolles A, de Los Reyes-Gavilán CG, Suárez A. Intestinal Dysbiosis Is Associated with Altered Short-Chain Fatty Acids and Serum-Free Fatty Acids in Systemic Lupus Erythematosus. Front Immunol 2017;8:23. [PMID: 28167944 DOI: 10.3389/fimmu.2017.00023] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 10.0] [Reference Citation Analysis]
161 Bilic-Curcic I, Cigrovski Berkovic M, Virovic-Jukic L, Mrzljak A. Shifting perspectives - interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals. World J Hepatol 2021;13:80-93. [PMID: 33584988 DOI: 10.4254/wjh.v13.i1.80] [Reference Citation Analysis]
162 Miele L, Gasbarrini G, Giorgio V, Gasbarrini A, Grieco A. Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. Intern Emerg Med 2016;11:3-10. [PMID: 26602387 DOI: 10.1007/s11739-015-1346-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
163 Koehler BC, Arslic-Schmitt T, Peccerella T, Scherr AL, Schulze-Bergkamen H, Bruckner T, Gdynia G, Jäger D, Mueller S, Bartsch H, Seitz HK. Possible Mechanisms of Ethanol-Mediated Colorectal Carcinogenesis: The Role of Cytochrome P4502E1, Etheno-DNA Adducts, and the Anti-Apoptotic Protein Mcl-1. Alcohol Clin Exp Res 2016;40:2094-101. [PMID: 27581253 DOI: 10.1111/acer.13180] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
164 Flisiak-Jackiewicz M, Lebensztejn DM. Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children. Clin Exp Hepatol 2019;5:11-21. [PMID: 30915402 DOI: 10.5114/ceh.2019.83152] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
165 Sheng L, Jena PK, Liu HX, Kalanetra KM, Gonzalez FJ, French SW, Krishnan VV, Mills DA, Wan YY. Gender Differences in Bile Acids and Microbiota in Relationship with Gender Dissimilarity in Steatosis Induced by Diet and FXR Inactivation. Sci Rep. 2017;7:1748. [PMID: 28496104 DOI: 10.1038/s41598-017-01576-9] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 15.0] [Reference Citation Analysis]
166 Wijarnpreecha K, Lou S, Watthanasuntorn K, Kroner PT, Cheungpasitporn W, Lukens FJ, Pungpapong S, Keaveny AP, Ungprasert P. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2020;32:601-8. [PMID: 31567712 DOI: 10.1097/MEG.0000000000001541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 12.0] [Reference Citation Analysis]
167 Jia N, Lin X, Ma S, Ge S, Mu S, Yang C, Shi S, Gao L, Xu J, Bo T, Zhao J. Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a in Gynostemma pentaphylla (Thunb.) Makino treated mice. Nutr Metab (Lond) 2018;15:86. [PMID: 30555521 DOI: 10.1186/s12986-018-0323-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
168 Jobira B, Frank DN, Silveira LJ, Pyle L, Kelsey MM, Garcia-Reyes Y, Robertson CE, Ir D, Nadeau KJ, Cree-Green M. Hepatic steatosis relates to gastrointestinal microbiota changes in obese girls with polycystic ovary syndrome. PLoS One 2021;16:e0245219. [PMID: 33465100 DOI: 10.1371/journal.pone.0245219] [Reference Citation Analysis]
169 Nobili V, Putignani L, Mosca A, Chierico FD, Vernocchi P, Alisi A, Stronati L, Cucchiara S, Toscano M, Drago L. Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players? Arch Med Sci. 2018;14:81-87. [PMID: 29379536 DOI: 10.5114/aoms.2016.62150] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
170 Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome 2016;4:30. [PMID: 27338587 DOI: 10.1186/s40168-016-0171-4] [Cited by in Crossref: 140] [Cited by in F6Publishing: 114] [Article Influence: 28.0] [Reference Citation Analysis]
171 Engstler AJ, Aumiller T, Degen C, Dürr M, Weiss E, Maier IB, Schattenberg JM, Jin CJ, Sellmann C, Bergheim I. Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut. 2016;65:1564-1571. [PMID: 26006114 DOI: 10.1136/gutjnl-2014-308379] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 10.0] [Reference Citation Analysis]
172 Scapaticci S, D'Adamo E, Mohn A, Chiarelli F, Giannini C. Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes.Front Endocrinol (Lausanne). 2021;12:639548. [PMID: 33889132 DOI: 10.3389/fendo.2021.639548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
173 Longo L, Tonin Ferrari J, Rampelotto PH, Hirata Dellavia G, Pasqualotto A, P Oliveira C, Thadeu Schmidt Cerski C, Reverbel da Silveira T, Uribe-Cruz C, Álvares-da-Silva MR. Gut Dysbiosis and Increased Intestinal Permeability Drive microRNAs, NLRP-3 Inflammasome and Liver Fibrosis in a Nutritional Model of Non-Alcoholic Steatohepatitis in Adult Male Sprague Dawley Rats. Clin Exp Gastroenterol 2020;13:351-68. [PMID: 32982365 DOI: 10.2147/CEG.S262879] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
174 Bajaj JS, Khoruts A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. Journal of Hepatology 2020;72:1003-27. [DOI: 10.1016/j.jhep.2020.01.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 34.0] [Reference Citation Analysis]
175 Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med 2021;10:467. [PMID: 33530440 DOI: 10.3390/jcm10030467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
176 Jiang X, Zheng J, Zhang S, Wang B, Wu C, Guo X. Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. Front Med (Lausanne) 2020;7:361. [PMID: 32850884 DOI: 10.3389/fmed.2020.00361] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
177 Ramakrishna BS. Role of the gut microbiota in human nutrition and metabolism: Role of the gut microbiota. J Gastroenterol Hepatol 2013;28:9-17. [DOI: 10.1111/jgh.12294] [Cited by in Crossref: 198] [Cited by in F6Publishing: 151] [Article Influence: 24.8] [Reference Citation Analysis]
178 Temraz S, Nassar F, Kreidieh F, Mukherji D, Shamseddine A, Nasr R. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. Int J Mol Sci 2021;22:7800. [PMID: 34360566 DOI: 10.3390/ijms22157800] [Reference Citation Analysis]
179 Janssen AWF, Kersten S. The role of the gut microbiota in metabolic health. The FASEB Journal 2015;29:3111-23. [DOI: 10.1096/fj.14-269514] [Cited by in Crossref: 99] [Cited by in F6Publishing: 77] [Article Influence: 16.5] [Reference Citation Analysis]
180 Aron-wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279-97. [DOI: 10.1038/s41575-020-0269-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 82] [Article Influence: 103.0] [Reference Citation Analysis]
181 Moszak M, Szulińska M, Walczak-Gałęzewska M, Bogdański P. Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. Int J Environ Res Public Health 2021;18:1616. [PMID: 33567710 DOI: 10.3390/ijerph18041616] [Reference Citation Analysis]
182 Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr 2013;56:461-8. [PMID: 23287807 DOI: 10.1097/MPG.0b013e318284abb5] [Cited by in Crossref: 117] [Cited by in F6Publishing: 52] [Article Influence: 14.6] [Reference Citation Analysis]
183 Shin NR, Bose S, Wang JH, Ansari A, Lim SK, Chin YW, Choi HS, Kim H. Flos Lonicera Combined with Metformin Ameliorates Hepatosteatosis and Glucose Intolerance in Association with Gut Microbiota Modulation. Front Microbiol. 2017;8:2271. [PMID: 29204141 DOI: 10.3389/fmicb.2017.02271] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
184 Xie C, Halegoua-DeMarzio D. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter? Nutrients. 2019;11. [PMID: 31752378 DOI: 10.3390/nu11112837] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
185 Tabibian JH, Varghese C, LaRusso NF, O'Hara SP. The enteric microbiome in hepatobiliary health and disease. Liver Int 2016;36:480-7. [PMID: 26561779 DOI: 10.1111/liv.13009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
186 Satapathy SK, Banerjee P, Pierre JF, Higgins D, Dutta S, Heda R, Khan SD, Mupparaju VK, Mas V, Nair S, Eason JD, Kleiner DE, Maluf DG. Characterization of Gut Microbiome in Liver Transplant Recipients With Nonalcoholic Steatohepatitis. Transplant Direct 2020;6:e625. [PMID: 33204823 DOI: 10.1097/TXD.0000000000001033] [Reference Citation Analysis]
187 Zhu L, Baker RD, Baker SS. Gut microbiome and nonalcoholic fatty liver diseases. Pediatr Res. 2015;77:245-251. [PMID: 25310763 DOI: 10.1038/pr.2014.157] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 10.4] [Reference Citation Analysis]
188 Liang Y, Liang S, Zhang Y, Deng Y, He Y, Chen Y, Liu C, Lin C, Yang Q. Oral Administration of Compound Probiotics Ameliorates HFD-Induced Gut Microbe Dysbiosis and Chronic Metabolic Inflammation via the G Protein-Coupled Receptor 43 in Non-alcoholic Fatty Liver Disease Rats. Probiotics Antimicrob Proteins. 2019;11:175-185. [PMID: 29353414 DOI: 10.1007/s12602-017-9378-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 19.0] [Reference Citation Analysis]
189 Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, Chen Y, Li L. Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. Sci Rep 2016;6:32002. [PMID: 27550547 DOI: 10.1038/srep32002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 102] [Article Influence: 22.8] [Reference Citation Analysis]
190 Pérez-Montes de Oca A, Julián MT, Ramos A, Puig-Domingo M, Alonso N. Microbiota, Fiber, and NAFLD: Is There Any Connection? Nutrients 2020;12:E3100. [PMID: 33053631 DOI: 10.3390/nu12103100] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
191 Visschers RG, Luyer MD, Schaap FG, Olde Damink SW, Soeters PB. The gut-liver axis. Curr Opin Clin Nutr Metab Care. 2013;16:576-581. [PMID: 23873346 DOI: 10.1097/mco.0b013e32836410a4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 17] [Article Influence: 5.9] [Reference Citation Analysis]
192 Malaguarnera G, Giordano M, Nunnari G, Bertino G, Malaguarnera M. Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives. World J Gastroenterol. 2014;20:16639-16648. [PMID: 25469033 DOI: 10.3748/wjg.v20.i44.16639] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 59] [Article Influence: 11.8] [Reference Citation Analysis]
193 Gupta H, Youn GS, Shin MJ, Suk KT. Role of Gut Microbiota in Hepatocarcinogenesis. Microorganisms. 2019;7:pii: E121. [PMID: 31060311 DOI: 10.3390/microorganisms7050121] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 19.5] [Reference Citation Analysis]
194 Paratore M, Santopaolo F, Cammarota G, Pompili M, Gasbarrini A, Ponziani FR. Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. J Clin Med 2021;10:2605. [PMID: 34204748 DOI: 10.3390/jcm10122605] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
196 Sugahara H, Okai S, Odamaki T, Wong CB, Kato K, Mitsuyama E, Xiao JZ, Shinkura R. Decreased Taxon-Specific IgA Response in Relation to the Changes of Gut Microbiota Composition in the Elderly. Front Microbiol 2017;8:1757. [PMID: 28955323 DOI: 10.3389/fmicb.2017.01757] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
197 Schwimmer JB, Johnson JS, Angeles JE, Behling C, Belt PH, Borecki I, Bross C, Durelle J, Goyal NP, Hamilton G, Holtz ML, Lavine JE, Mitreva M, Newton KP, Pan A, Simpson PM, Sirlin CB, Sodergren E, Tyagi R, Yates KP, Weinstock GM, Salzman NH. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;157:1109-22. [PMID: 31255652 DOI: 10.1053/j.gastro.2019.06.028] [Cited by in Crossref: 68] [Cited by in F6Publishing: 51] [Article Influence: 34.0] [Reference Citation Analysis]
198 Liu H, Chen T, Xie X, Wang X, Luo Y, Xu N, Sa Z, Zhang M, Chen Z, Hu X, Li J. Hepatic Lipidomics Analysis Reveals the Ameliorative Effects of Highland Barley β-Glucan on Western Diet-Induced Nonalcoholic Fatty Liver Disease Mice. J Agric Food Chem 2021;69:9287-98. [PMID: 34347479 DOI: 10.1021/acs.jafc.1c03379] [Reference Citation Analysis]
199 Quigley EM, Monsour HP. The gut microbiota and the liver: implications for clinical practice. Expert Rev Gastroenterol Hepatol 2013;7:723-32. [PMID: 24134195 DOI: 10.1586/17474124.2013.848167] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
200 Lee G, You HJ, Bajaj JS, Joo SK, Yu J, Park S, Kang H, Park JH, Kim JH, Lee DH, Lee S, Kim W, Ko G. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nat Commun 2020;11:4982. [PMID: 33020474 DOI: 10.1038/s41467-020-18754-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 28.0] [Reference Citation Analysis]
201 Iino C, Endo T, Mikami K, Hasegawa T, Kimura M, Sawada N, Nakaji S, Fukuda S. Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study. Hepatol Int 2019;13:748-56. [DOI: 10.1007/s12072-019-09987-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
202 Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017;25:1054-1062.e5. [PMID: 28467925 DOI: 10.1016/j.cmet.2017.04.001] [Cited by in Crossref: 349] [Cited by in F6Publishing: 298] [Article Influence: 116.3] [Reference Citation Analysis]
203 Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol Metab. 2013;24:537-545. [PMID: 23827477 DOI: 10.1016/j.tem.2013.05.009] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 13.3] [Reference Citation Analysis]
204 Yu J, Marsh S, Hu J, Feng W, Wu C. The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background. Gastroenterol Res Pract. 2016;2016:2862173. [PMID: 27247565 DOI: 10.1155/2016/2862173] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 11.4] [Reference Citation Analysis]
205 Ren SM, Zhang QZ, Chen ML, Jiang M, Zhou Y, Xu XJ, Wang DM, Pan YN, Liu XQ. Anti-NAFLD effect of defatted walnut powder extract in high fat diet-induced C57BL/6 mice by modulating the gut microbiota. J Ethnopharmacol 2021;270:113814. [PMID: 33444725 DOI: 10.1016/j.jep.2021.113814] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
206 Ding Y, Yanagi K, Cheng C, Alaniz RC, Lee K, Jayaraman A. Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites. Pharmacol Res. 2019;141:521-529. [PMID: 30660825 DOI: 10.1016/j.phrs.2019.01.029] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 13.5] [Reference Citation Analysis]
207 Mouzaki M, Loomba R. Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention. Therap Adv Gastroenterol 2019;12:1756284819858470. [PMID: 31258623 DOI: 10.1177/1756284819858470] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
208 Hirahatake KM, Bruno RS, Bolling BW, Blesso C, Alexander LM, Adams SH. Dairy Foods and Dairy Fats: New Perspectives on Pathways Implicated in Cardiometabolic Health. Adv Nutr 2020;11:266-79. [PMID: 31555799 DOI: 10.1093/advances/nmz105] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
209 Baker SS, Baker RD. Gut Microbiota and Liver Injury (II): Chronic Liver Injury. Adv Exp Med Biol 2020;1238:39-54. [PMID: 32323179 DOI: 10.1007/978-981-15-2385-4_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
210 Aw W, Fukuda S. The Role of Integrated Omics in Elucidating the Gut Microbiota Health Potentials. In: Liong M, editor. Beneficial Microorganisms in Medical and Health Applications. Cham: Springer International Publishing; 2015. pp. 73-100. [DOI: 10.1007/978-3-319-23213-3_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
211 Wong VW, Chitturi S, Wong GL, Yu J, Chan HL, Farrell GC. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol 2016;1:56-67. [PMID: 28404113 DOI: 10.1016/S2468-1253(16)30011-5] [Cited by in Crossref: 91] [Cited by in F6Publishing: 28] [Article Influence: 18.2] [Reference Citation Analysis]
212 Sookoian S, Pirola CJ. Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions. Hepatobiliary Surg Nutr 2021;10:337-49. [PMID: 34159161 DOI: 10.21037/hbsn-20-270] [Reference Citation Analysis]
213 Houben T, Brandsma E, Walenbergh SMA, Hofker MH, Shiri-Sverdlov R. Oxidized LDL at the crossroads of immunity in non-alcoholic steatohepatitis. Biochim Biophys Acta Mol Cell Biol Lipids 2017;1862:416-29. [PMID: 27472963 DOI: 10.1016/j.bbalip.2016.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
214 Jiang CM, Pu CW, Hou YH, Chen Z, Alanazy M, Hebbard L. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. World J Gastroenterol 2014;20:16464-73. [PMID: 25469014 DOI: 10.3748/wjg.v20.i44.16464] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
215 van Best N, Jansen PL, Rensen SS. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation. Hepatol Int. 2015;9:406-415. [PMID: 26067771 DOI: 10.1007/s12072-015-9640-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
216 Taniki N, Nakamoto N, Chu PS, Mikami Y, Amiya T, Teratani T, Suzuki T, Tsukimi T, Fukuda S, Yamaguchi A, Shiba S, Miyake R, Katayama T, Ebinuma H, Kanai T. Intestinal barrier regulates immune responses in the liver via IL-10-producing macrophages. JCI Insight 2018;3:91980. [PMID: 29925685 DOI: 10.1172/jci.insight.91980] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
217 Chen YR, Zheng HM, Zhang GX, Chen FL, Chen LD, Yang ZC. High Oscillospira abundance indicates constipation and low BMI in the Guangdong Gut Microbiome Project. Sci Rep 2020;10:9364. [PMID: 32518316 DOI: 10.1038/s41598-020-66369-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
218 Brandi G, De Lorenzo S, Candela M, Pantaleo MA, Bellentani S, Tovoli F, Saccoccio G, Biasco G. Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis 2017;38:231-40. [DOI: 10.1093/carcin/bgx007] [Cited by in Crossref: 104] [Cited by in F6Publishing: 44] [Article Influence: 26.0] [Reference Citation Analysis]
219 Gil-Gómez A, Brescia P, Rescigno M, Romero-Gómez M. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. Semin Liver Dis 2021;41:191-205. [PMID: 34107545 DOI: 10.1055/s-0041-1723752] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Ferrere G, Leroux A, Wrzosek L, Puchois V, Gaudin F, Ciocan D, Renoud ML, Naveau S, Perlemuter G, Cassard AM. Activation of Kupffer Cells Is Associated with a Specific Dysbiosis Induced by Fructose or High Fat Diet in Mice. PLoS One 2016;11:e0146177. [PMID: 26731543 DOI: 10.1371/journal.pone.0146177] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
221 Del Chierico F, Gnani D, Vernocchi P, Petrucca A, Alisi A, Dallapiccola B, Nobili V, Lorenza P. Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. Int J Mol Sci. 2014;15:684-711. [PMID: 24402126 DOI: 10.3390/ijms15010684] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
222 Rodriguez-Castaño GP, Caro-Quintero A, Reyes A, Lizcano F. Advances in Gut Microbiome Research, Opening New Strategies to Cope with a Western Lifestyle. Front Genet 2016;7:224. [PMID: 28119734 DOI: 10.3389/fgene.2016.00224] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
223 Jiang XW, Li YT, Ye JZ, Lv LX, Yang LY, Bian XY, Wu WR, Wu JJ, Shi D, Wang Q, Fang DQ, Wang KC, Wang QQ, Lu YM, Xie JJ, Li LJ. New strain of Pediococcus pentosaceus alleviates ethanol-induced liver injury by modulating the gut microbiota and short-chain fatty acid metabolism. World J Gastroenterol 2020;26:6224-40. [PMID: 33177795 DOI: 10.3748/wjg.v26.i40.6224] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
224 Velázquez KT, Enos RT, Bader JE, Sougiannis AT, Carson MS, Chatzistamou I, Carson JA, Nagarkatti PS, Nagarkatti M, Murphy EA. Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice. World J Hepatol 2019;11:619-37. [PMID: 31528245 DOI: 10.4254/wjh.v11.i8.619] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 20.5] [Reference Citation Analysis]
225 Safari Z, Bruneau A, Monnoye M, Mariadassou M, Philippe C, Zatloukal K, Gérard P. Murine Genetic Background Overcomes Gut Microbiota Changes to Explain Metabolic Response to High-Fat Diet. Nutrients 2020;12:E287. [PMID: 31973214 DOI: 10.3390/nu12020287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
226 Delli Bovi AP, Marciano F, Mandato C, Siano MA, Savoia M, Vajro P. Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review. Front Med (Lausanne) 2021;8:595371. [PMID: 33718398 DOI: 10.3389/fmed.2021.595371] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
227 Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412-425. [PMID: 27273168 DOI: 10.1038/nrgastro.2016.85] [Cited by in Crossref: 362] [Cited by in F6Publishing: 295] [Article Influence: 72.4] [Reference Citation Analysis]
228 Buss C, Valle-tovo C, Miozzo S, Mattos AAD. Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients. Annals of Hepatology 2014;13:482-8. [DOI: 10.1016/s1665-2681(19)31246-3] [Cited by in Crossref: 27] [Article Influence: 3.9] [Reference Citation Analysis]
229 Chen X, Zhang Z, Li H, Zhao J, Wei X, Lin W, Zhao X, Jiang A, Yuan J. Endogenous ethanol produced by intestinal bacteria induces mitochondrial dysfunction in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2020;35:2009-19. [PMID: 32150306 DOI: 10.1111/jgh.15027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
230 Annavajhala MK, Gomez-Simmonds A, Macesic N, Sullivan SB, Kress A, Khan SD, Giddins MJ, Stump S, Kim GI, Narain R, Verna EC, Uhlemann AC. Colonizing multidrug-resistant bacteria and the longitudinal evolution of the intestinal microbiome after liver transplantation. Nat Commun 2019;10:4715. [PMID: 31624266 DOI: 10.1038/s41467-019-12633-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
231 Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology 2014;59:328-39. [PMID: 23703735 DOI: 10.1002/hep.26494] [Cited by in Crossref: 181] [Cited by in F6Publishing: 172] [Article Influence: 22.6] [Reference Citation Analysis]
232 Gao YS, Qian MY, Wei QQ, Duan XB, Wang SL, Hu HY, Liu J, Pan CY, Zhang SQ, Qi LW, Zhou JP, Zhang HB, Wang LR. WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice. Acta Pharmacol Sin 2020;41:336-47. [PMID: 31645659 DOI: 10.1038/s41401-019-0310-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
233 Ma J, Sheng L, Hong Y, Xi C, Gu Y, Zheng N, Li M, Chen L, Wu G, Li Y, Yan J, Han R, Li B, Qiu H, Zhong J, Jia W, Li H. Variations of Gut Microbiome Profile Under Different Storage Conditions and Preservation Periods: A Multi-Dimensional Evaluation. Front Microbiol 2020;11:972. [PMID: 32536906 DOI: 10.3389/fmicb.2020.00972] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
234 Song L, Li Y, Qu D, Ouyang P, Ding X, Wu P, Guan Q, Yang L. The regulatory effects of phytosterol esters (PSEs) on gut flora and faecal metabolites in rats with NAFLD. Food Funct 2020;11:977-91. [PMID: 31803887 DOI: 10.1039/c9fo01570a] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
235 Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038-1048. [PMID: 26823198 DOI: 10.1016/j.metabol.2015.12.012] [Cited by in Crossref: 901] [Cited by in F6Publishing: 742] [Article Influence: 180.2] [Reference Citation Analysis]
236 Milosevic I, Russo E, Vujovic A, Barac A, Stevanovic O, Gitto S, Amedei A. Microbiota and viral hepatitis: State of the art of a complex matter. WJG 2021;27:5488-501. [DOI: 10.3748/wjg.v27.i33.5488] [Reference Citation Analysis]
237 Capurso L. Thirty Years of Lactobacillus rhamnosus GG: A Review. J Clin Gastroenterol 2019;53 Suppl 1:S1-S41. [PMID: 30741841 DOI: 10.1097/MCG.0000000000001170] [Cited by in Crossref: 50] [Cited by in F6Publishing: 20] [Article Influence: 50.0] [Reference Citation Analysis]
238 Caussy C, Hsu C, Lo MT, Liu A, Bettencourt R, Ajmera VH, Bassirian S, Hooker J, Sy E, Richards L, Schork N, Schnabl B, Brenner DA, Sirlin CB, Chen CH, Loomba R; Genetics of NAFLD in Twins Consortium. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. 2018;68:918-932. [PMID: 29572891 DOI: 10.1002/hep.29892] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 22.7] [Reference Citation Analysis]
239 Ren X, Gamallat Y, Liu D, Zhu Y, Meyiah A, Yan C, Shang D, Xin Y. The distribution characteristics of intestinal microbiota in children with community-acquired pneumonia under five Years of age. Microb Pathog 2020;142:104062. [PMID: 32058024 DOI: 10.1016/j.micpath.2020.104062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
240 Schwenger KJP, Bolzon CM, Li C, Allard JP. Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria. Eur J Nutr 2019;58:1771-84. [PMID: 30306296 DOI: 10.1007/s00394-018-1844-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
241 Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol 2015;1:275-84. [PMID: 26090511 DOI: 10.1016/j.jcmgh.2015.04.003] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 15.5] [Reference Citation Analysis]
242 Lang S, Farowski F, Martin A, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Lammert F, Goeser T, Steffen HM, Demir M. Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools. Sci Rep 2020;10:9385. [PMID: 32523101 DOI: 10.1038/s41598-020-66241-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
243 Gophna U, Konikoff T, Nielsen HB. Oscillospira and related bacteria - From metagenomic species to metabolic features. Environ Microbiol. 2017;19:835-841. [PMID: 28028921 DOI: 10.1111/1462-2920.13658] [Cited by in Crossref: 131] [Cited by in F6Publishing: 114] [Article Influence: 32.8] [Reference Citation Analysis]
244 Luther J, Garber JJ, Khalili H, Dave M, Bale SS, Jindal R, Motola DL, Luther S, Bohr S, Jeoung SW, Deshpande V, Singh G, Turner JR, Yarmush ML, Chung RT, Patel SJ. Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability. Cell Mol Gastroenterol Hepatol 2015;1:222-32. [PMID: 26405687 DOI: 10.1016/j.jcmgh.2015.01.001] [Cited by in Crossref: 119] [Cited by in F6Publishing: 102] [Article Influence: 19.8] [Reference Citation Analysis]
245 Araújo JR, Tomas J, Brenner C, Sansonetti PJ. Impact of high-fat diet on the intestinal microbiota and small intestinal physiology before and after the onset of obesity. Biochimie 2017;141:97-106. [PMID: 28571979 DOI: 10.1016/j.biochi.2017.05.019] [Cited by in Crossref: 114] [Cited by in F6Publishing: 90] [Article Influence: 28.5] [Reference Citation Analysis]
246 Mehmood A, Zhao L, Wang Y, Pan F, Hao S, Zhang H, Iftikhar A, Usman M. Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive review. Food Res Int 2021;142:110180. [PMID: 33773656 DOI: 10.1016/j.foodres.2021.110180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
247 Xu H, Wei Y, Ma H, Liu Y, Zhang Y, Hu L, Li J. Alterations of Gut Microbiome in the Patients With Severe Fever With Thrombocytopenia Syndrome. Front Microbiol 2018;9:2315. [PMID: 30327643 DOI: 10.3389/fmicb.2018.02315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
248 Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, Hu Y, Li J, Liu Y. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096. [PMID: 25644696 DOI: 10.1038/srep08096] [Cited by in Crossref: 253] [Cited by in F6Publishing: 224] [Article Influence: 42.2] [Reference Citation Analysis]
249 Zhuo L, Xu J, You N, Wang L, Song Y, Luo Y, Shi J. Study on the new strategy and key techniques for accurate prevention and treatment of nonalcoholic steatohepatitis based on intestinal target bacteria. Medicine (Baltimore) 2020;99:e22867. [PMID: 33327227 DOI: 10.1097/MD.0000000000022867] [Reference Citation Analysis]
250 Tuohy KM, Fava F, Viola R. ‘The way to a man’s heart is through his gut microbiota’--dietary pro- and prebiotics for the management of cardiovascular risk. Proc Nutr Soc. 2014;73:172-185. [PMID: 24495527 DOI: 10.1017/s0029665113003911] [Cited by in Crossref: 80] [Cited by in F6Publishing: 27] [Article Influence: 11.4] [Reference Citation Analysis]
251 Jiang L, Schnabl B. Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know? Physiology (Bethesda) 2020;35:261-74. [PMID: 32490750 DOI: 10.1152/physiol.00005.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
252 Milosevic I, Vujovic A, Barac A, Djelic M, Korac M, Radovanovic Spurnic A, Gmizic I, Stevanovic O, Djordjevic V, Lekic N, Russo E, Amedei A. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. Int J Mol Sci. 2019;20:395. [PMID: 30658519 DOI: 10.3390/ijms20020395] [Cited by in Crossref: 82] [Cited by in F6Publishing: 62] [Article Influence: 41.0] [Reference Citation Analysis]
253 Hong M, Han DH, Hong J, Kim DJ, Suk KT. Are Probiotics Effective in Targeting Alcoholic Liver Diseases? Probiotics Antimicrob Proteins 2019;11:335-47. [PMID: 29687200 DOI: 10.1007/s12602-018-9419-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
254 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3748/wjg.v20.i7.1712] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 67] [Article Influence: 12.7] [Reference Citation Analysis]
255 Fielding CM, Angulo P. Hepatic steatosis and steatohepatitis: Are they really two distinct entities? Curr Hepatol Rep 2014;13:151-8. [PMID: 24977111 DOI: 10.1007/s11901-014-0227-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
256 D'Adamo E, Castorani V, Nobili V. The Liver in Children With Metabolic Syndrome. Front Endocrinol (Lausanne) 2019;10:514. [PMID: 31428049 DOI: 10.3389/fendo.2019.00514] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
257 Jian C, Luukkonen P, Sädevirta S, Yki-Järvinen H, Salonen A. Impact of short-term overfeeding of saturated or unsaturated fat or sugars on the gut microbiota in relation to liver fat in obese and overweight adults. Clin Nutr 2021;40:207-16. [PMID: 32536582 DOI: 10.1016/j.clnu.2020.05.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
258 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 30.0] [Reference Citation Analysis]
259 Alferink LJM, Radjabzadeh D, Erler NS, Vojinovic D, Medina-Gomez C, Uitterlinden AG, de Knegt RJ, Amin N, Ikram MA, Janssen HLA, Kiefte-de Jong JC, Metselaar HJ, van Duijn CM, Kraaij R, Darwish Murad S. Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults.Hepatology. 2021;73:968-982. [PMID: 32530501 DOI: 10.1002/hep.31417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
260 Wong VW, Tse CH, Lam TT, Wong GL, Chim AM, Chu WC, Yeung DK, Law PT, Kwan HS, Yu J, Sung JJ, Chan HL. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. PLoS One. 2013;8:e62885. [PMID: 23638162 DOI: 10.1371/journal.pone.0062885] [Cited by in Crossref: 166] [Cited by in F6Publishing: 148] [Article Influence: 20.8] [Reference Citation Analysis]
261 de Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M. Fecal microbiota transplantation in metabolic syndrome: History, present and future. Gut Microbes. 2017;8:253-267. [PMID: 28609252 DOI: 10.1080/19490976.2017.1293224] [Cited by in Crossref: 110] [Cited by in F6Publishing: 83] [Article Influence: 27.5] [Reference Citation Analysis]
262 Okubo H, Nakatsu Y, Sakoda H, Kushiyama A, Fujishiro M, Fukushima T, Matsunaga Y, Ohno H, Yoneda M, Kamata H, Shinjo T, Iwashita M, Nishimura F, Asano T. Mosapride citrate improves nonalcoholic steatohepatitis with increased fecal lactic acid bacteria and plasma glucagon-like peptide-1 level in a rodent model. Am J Physiol Gastrointest Liver Physiol 2015;308:G151-8. [PMID: 25428903 DOI: 10.1152/ajpgi.00198.2014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
263 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
264 Porras D, Nistal E, Martínez-Flórez S, González-Gallego J, García-Mediavilla MV, Sánchez-Campos S. Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. Front Physiol 2018;9:1813. [PMID: 30618824 DOI: 10.3389/fphys.2018.01813] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
265 Vernekar M, Singhal R, Joshi K, Amarapurkar D. Variation in the Plasma Levels of Polyunsaturated Fatty Acids in Control vis-à-vis Nonalcoholic Fatty Liver Disease Subjects and Its Possible Association with Gut Microbiome. Metab Syndr Relat Disord 2018;16:329-35. [PMID: 29873593 DOI: 10.1089/met.2018.0008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
266 Idalsoaga F, Kulkarni AV, Mousa OY, Arrese M, Arab JP. Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities. Front Med (Lausanne) 2020;7:448. [PMID: 32974366 DOI: 10.3389/fmed.2020.00448] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
267 Houttu V, Boulund U, Grefhorst A, Soeters MR, Pinto-Sietsma SJ, Nieuwdorp M, Holleboom AG. The role of the gut microbiome and exercise in non-alcoholic fatty liver disease. Therap Adv Gastroenterol 2020;13:1756284820941745. [PMID: 32973925 DOI: 10.1177/1756284820941745] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
268 Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Digestive and Liver Disease 2015;47:181-90. [DOI: 10.1016/j.dld.2014.09.020] [Cited by in Crossref: 371] [Cited by in F6Publishing: 300] [Article Influence: 61.8] [Reference Citation Analysis]
269 Saltzman ET, Palacios T, Thomsen M, Vitetta L. Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. Front Microbiol 2018;9:61. [PMID: 29441049 DOI: 10.3389/fmicb.2018.00061] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 21.3] [Reference Citation Analysis]
270 Ainonen S, Tejesvi MV, Mahmud MR, Paalanne N, Pokka T, Li W, Nelson KE, Salo J, Renko M, Vänni P, Pirttilä AM, Tapiainen T. Antibiotics at birth and later antibiotic courses: effects on gut microbiota. Pediatr Res 2021. [PMID: 33824448 DOI: 10.1038/s41390-021-01494-7] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
271 Hamid H, Zhang JY, Li WX, Liu C, Li ML, Zhao LH, Ji C, Ma QG. Interactions between the cecal microbiota and non-alcoholic steatohepatitis using laying hens as the model. Poult Sci 2019;98:2509-21. [PMID: 30690636 DOI: 10.3382/ps/pey596] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
272 Betrapally NS, Gillevet PM, Bajaj JS. Gut microbiome and liver disease. Transl Res. 2017;179:49-59. [PMID: 27477080 DOI: 10.1016/j.trsl.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 8.6] [Reference Citation Analysis]
273 Kessoku T, Kobayashi T, Tanaka K, Yamamoto A, Takahashi K, Iwaki M, Ozaki A, Kasai Y, Nogami A, Honda Y, Ogawa Y, Kato S, Imajo K, Higurashi T, Hosono K, Yoneda M, Usuda H, Wada K, Saito S, Nakajima A. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. Int J Mol Sci 2021;22:8161. [PMID: 34360923 DOI: 10.3390/ijms22158161] [Reference Citation Analysis]
274 Park SY, Hwang BO, Lim M, Ok SH, Lee SK, Chun KS, Park KK, Hu Y, Chung WY, Song NY. Oral-Gut Microbiome Axis in Gastrointestinal Disease and Cancer. Cancers (Basel) 2021;13:2124. [PMID: 33924899 DOI: 10.3390/cancers13092124] [Reference Citation Analysis]
275 Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016;65:1038-48. [DOI: 10.1016/j.metabol.2015.12.012] [Reference Citation Analysis]
276 Bao T, He F, Zhang X, Zhu L, Wang Z, Lu H, Wang T, Li Y, Yang S, Wang H. Inulin Exerts Beneficial Effects on Non-Alcoholic Fatty Liver Disease via Modulating gut Microbiome and Suppressing the Lipopolysaccharide-Toll-Like Receptor 4-Mψ-Nuclear Factor-κB-Nod-Like Receptor Protein 3 Pathway via gut-Liver Axis in Mice. Front Pharmacol 2020;11:558525. [PMID: 33390939 DOI: 10.3389/fphar.2020.558525] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
277 Barbuti RC, Schiavon LL, Oliveira CP, Alvares-DA-Silva MR, Sassaki LY, Passos MDCF, Farias AQ, Barros LL, Barreto BP, Albuquerque GBML, Alves AM, Navarro-Rodriguez T, Bittencourt PL. GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN GASTROINTESTINAL AND LIVER DISEASES: PROCEEDINGS OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN NUCLEUS FOR THE STUDY OF HELICOBACTER PYLORI AND MICROBIOTA (NBEHPM), AND BRAZILIAN FEDERATION OF GASTROENTEROLOGY (FBG). Arq Gastroenterol 2020;57:381-98. [PMID: 33331485 DOI: 10.1590/S0004-2803.202000000-72] [Reference Citation Analysis]
278 Qiu Y, Wang S, Wan T, Ye M, Jiang R, Pei L, Yang L. Blood-based novel biomarkers for nonalcoholic steatohepatitis. Biomark Med 2018;12:501-15. [PMID: 29712439 DOI: 10.2217/bmm-2017-0361] [Reference Citation Analysis]
279 Pritchard MT, McCracken JM. Identifying Novel Targets for Treatment of Liver Fibrosis: What Can We Learn from Injured Tissues which Heal Without a Scar? Curr Drug Targets 2015;16:1332-46. [PMID: 26302807 DOI: 10.2174/1389450116666150825111439] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
280 Sung H, Kim SW, Hong M, Suk KT. Microbiota-based treatments in alcoholic liver disease. World J Gastroenterol 2016;22:6673-82. [PMID: 27547010 DOI: 10.3748/wjg.v22.i29.6673] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
281 Qian M, Hu H, Yao Y, Zhao D, Wang S, Pan C, Duan X, Gao Y, Liu J, Zhang Y, Yang S, Qi LW, Wang L. Coordinated changes of gut microbiome and lipidome differentiates nonalcoholic steatohepatitis (NASH) from isolated steatosis. Liver Int 2020;40:622-37. [PMID: 31782595 DOI: 10.1111/liv.14316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
282 Picot D, Layec S, Dussaulx L, Trivin F, Thibault R. Chyme reinfusion in patients with intestinal failure due to temporary double enterostomy: A 15-year prospective cohort in a referral centre. Clinical Nutrition 2017;36:593-600. [DOI: 10.1016/j.clnu.2016.04.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
283 Kim AS, Ko HJ. Plasma concentrations of zonulin are elevated in obese men with fatty liver disease. Diabetes Metab Syndr Obes 2018;11:149-57. [PMID: 29719415 DOI: 10.2147/DMSO.S163062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
284 Reid D, Mcdonald B, Khalid T, Vo T, Schenck L, Surette M, Beck P, Reimer R, Probert C, Rioux K, Eksteen B. Unique microbial-derived volatile organic compounds in portal venous circulation in murine non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2016;1862:1337-44. [DOI: 10.1016/j.bbadis.2016.04.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
285 Sookoian S, Pirola CJ. How Safe Is Moderate Alcohol Consumption in Overweight and Obese Individuals? Gastroenterology 2016;150:1698-1703.e2. [PMID: 26775630 DOI: 10.1053/j.gastro.2016.01.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
286 Khan A, Ding Z, Ishaq M, Bacha AS, Khan I, Hanif A, Li W, Guo X. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates. Int J Biol Sci 2021;17:818-33. [PMID: 33767591 DOI: 10.7150/ijbs.56214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
287 Wang Z, Zeng M, Wang Z, Qin F, Chen J, He Z. Dietary Polyphenols to Combat Nonalcoholic Fatty Liver Disease via the Gut-Brain-Liver Axis: A Review of Possible Mechanisms. J Agric Food Chem 2021;69:3585-600. [PMID: 33729777 DOI: 10.1021/acs.jafc.1c00751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Reference Citation Analysis]
289 Moffett JR, Puthillathu N, Vengilote R, Jaworski DM, Namboodiri AM. Acetate Revisited: A Key Biomolecule at the Nexus of Metabolism, Epigenetics, and Oncogenesis - Part 2: Acetate and ACSS2 in Health and Disease. Front Physiol 2020;11:580171. [PMID: 33304273 DOI: 10.3389/fphys.2020.580171] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
290 Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;50:628-639. [PMID: 31373710 DOI: 10.1111/apt.15416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
291 Chen J, Thomsen M, Vitetta L. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. J Cell Biochem 2019;120:2713-20. [PMID: 30443932 DOI: 10.1002/jcb.27635] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 12.7] [Reference Citation Analysis]
292 Jiang JW, Chen XH, Ren Z, Zheng SS. Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis. Hepatobiliary Pancreat Dis Int 2019;18:19-27. [PMID: 30527903 DOI: 10.1016/j.hbpd.2018.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
293 Zhao T, Zhan L, Zhou W, Chen W, Luo J, Zhang L, Weng Z, Zhao C, Liu S. The Effects of Erchen Decoction on Gut Microbiota and Lipid Metabolism Disorders in Zucker Diabetic Fatty Rats. Front Pharmacol 2021;12:647529. [PMID: 34366839 DOI: 10.3389/fphar.2021.647529] [Reference Citation Analysis]
294 Vespasiani-Gentilucci U, Gallo P, Picardi A. The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention. Arch Med Sci 2018;14:701-6. [PMID: 29765460 DOI: 10.5114/aoms.2016.58831] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
295 Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. Microbiome 2019;7:91. [PMID: 31196177 DOI: 10.1186/s40168-019-0704-8] [Cited by in Crossref: 216] [Cited by in F6Publishing: 157] [Article Influence: 108.0] [Reference Citation Analysis]
296 Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:15518-15531. [PMID: 25400436 DOI: 10.3748/wjg.v20.i42.15518] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 75] [Article Influence: 14.3] [Reference Citation Analysis]
297 Ciocan D, Cassard AM. [Intestinal bacteria involved in nutritional liver disease killed by phagotherapy: a new therapeutic target]. Med Sci (Paris) 2020;36:310-2. [PMID: 32356701 DOI: 10.1051/medsci/2020052] [Reference Citation Analysis]
298 Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr 2020;14:1875-87. [PMID: 32998095 DOI: 10.1016/j.dsx.2020.09.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
299 Wei X, Bottoms KA, Stein HH, Blavi L, Bradley CL, Bergstrom J, Knapp J, Story R, Maxwell C, Tsai T, Zhao J. Dietary Organic Acids Modulate Gut Microbiota and Improve Growth Performance of Nursery Pigs. Microorganisms 2021;9:E110. [PMID: 33466376 DOI: 10.3390/microorganisms9010110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
300 Cortez-Pinto H, Borralho P, Machado J, Lopes MT, Gato IV, Santos AM, Guerreiro AS. Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH). GE Port J Gastroenterol 2016;23:132-41. [PMID: 28868449 DOI: 10.1016/j.jpge.2016.01.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
301 Wang Y, Wang B, Wu J, Jiang X, Tang H, Nielsen OH. Modulation of Gut Microbiota in Pathological States. Engineering 2017;3:83-9. [DOI: 10.1016/j.eng.2017.01.013] [Cited by in Crossref: 16] [Article Influence: 4.0] [Reference Citation Analysis]
302 Pang J, Xu W, Zhang X, Wong GL, Chan AW, Chan H, Tse C, Shu SS, Choi PC, Chan HL, Yu J, Wong VW. Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;46:175-82. [DOI: 10.1111/apt.14119] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
303 Bomhof MR, Parnell JA, Ramay HR, Crotty P, Rioux KP, Probert CS, Jayakumar S, Raman M, Reimer RA. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. Eur J Nutr 2019;58:1735-45. [PMID: 29779170 DOI: 10.1007/s00394-018-1721-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
304 de Oliveira Neves VG, de Oliveira DT, Oliveira DC, Oliveira Perucci L, Dos Santos TAP, da Costa Fernandes I, de Sousa GG, Barboza NR, Guerra-Sá R. High-sugar diet intake, physical activity, and gut microbiota crosstalk: Implications for obesity in rats. Food Sci Nutr 2020;8:5683-95. [PMID: 33133570 DOI: 10.1002/fsn3.1842] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
305 Woźniak MK, Wiergowski M, Namieśnik J, Biziuk M. Biomarkers of Alcohol Consumption in Body Fluids - Possibilities and Limitations of Application in Toxicological Analysis. Curr Med Chem 2019;26:177-96. [PMID: 28982313 DOI: 10.2174/0929867324666171005111911] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
306 Grigor'eva IN. Gallstone Disease, Obesity and the Firmicutes/Bacteroidetes Ratio as a Possible Biomarker of Gut Dysbiosis. J Pers Med 2020;11:13. [PMID: 33375615 DOI: 10.3390/jpm11010013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
307 May PA, Hamrick KJ, Corbin KD, Hasken JM, Marais AS, Blankenship J, Hoyme HE, Gossage JP. Maternal nutritional status as a contributing factor for the risk of fetal alcohol spectrum disorders. Reprod Toxicol 2016;59:101-8. [PMID: 26656914 DOI: 10.1016/j.reprotox.2015.11.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
308 Liang S, Zhang Y, Deng Y, He Y, Liang Y, Liang Z, Chen Y, Tang K, Chen R, Yang Q. The Potential Effect of Chinese Herbal Formula Hongqijiangzhi Fang in Improving NAFLD: Focusing on NLRP3 Inflammasome and Gut Microbiota. Evid Based Complement Alternat Med 2018;2018:5378961. [PMID: 29675053 DOI: 10.1155/2018/5378961] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
309 Tan H, Nie S. Functional hydrocolloids, gut microbiota and health: picking food additives for personalized nutrition. FEMS Microbiol Rev 2021:fuaa065. [PMID: 33512498 DOI: 10.1093/femsre/fuaa065] [Reference Citation Analysis]
310 Hu H, Lin A, Kong M, Yao X, Yin M, Xia H, Ma J, Liu H. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol 2020;55:142-58. [PMID: 31845054 DOI: 10.1007/s00535-019-01649-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
311 Akiyama K, Warabi E, Okada K, Yanagawa T, Ishii T, Kose K, Tokushige K, Ishige K, Mizokami Y, Yamagata K, Onizawa K, Ariizumi SI, Yamamoto M, Shoda J. Deletion of both p62 and Nrf2 spontaneously results in the development of nonalcoholic steatohepatitis. Exp Anim 2018;67:201-18. [PMID: 29276215 DOI: 10.1538/expanim.17-0112] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
312 Rom O, Liu Y, Liu Z, Zhao Y, Wu J, Ghrayeb A, Villacorta L, Fan Y, Chang L, Wang L, Liu C, Yang D, Song J, Rech JC, Guo Y, Wang H, Zhao G, Liang W, Koike Y, Lu H, Koike T, Hayek T, Pennathur S, Xi C, Wen B, Sun D, Garcia-Barrio MT, Aviram M, Gottlieb E, Mor I, Liu W, Zhang J, Chen YE. Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Sci Transl Med 2020;12:eaaz2841. [PMID: 33268508 DOI: 10.1126/scitranslmed.aaz2841] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
313 Hartmann P, Chu H, Duan Y, Schnabl B. Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either. Am J Physiol Gastrointest Liver Physiol 2019;316:G563-73. [PMID: 30767680 DOI: 10.1152/ajpgi.00370.2018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
314 Wieland A, Frank DN, Harnke B, Bambha K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2015;42:1051-1063. [PMID: 26304302 DOI: 10.1111/apt.13376] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 17.0] [Reference Citation Analysis]
315 Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of Insulin Resistance in MAFLD. Int J Mol Sci 2021;22:4156. [PMID: 33923817 DOI: 10.3390/ijms22084156] [Reference Citation Analysis]
316 Cabrera-Rubio R, Patterson AM, Cotter PD, Beraza N. Cholestasis induced by bile duct ligation promotes changes in the intestinal microbiome in mice. Sci Rep 2019;9:12324. [PMID: 31444478 DOI: 10.1038/s41598-019-48784-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
317 Abdul-Hai A, Abdallah A, Malnick SD. Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease. World J Hepatol 2015;7:1679-84. [PMID: 26140087 DOI: 10.4254/wjh.v7.i12.1679] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
318 Adams LA, Wang Z, Liddle C, Melton PE, Ariff A, Chandraratna H, Tan J, Ching H, Coulter S, de Boer B, Christophersen CT, O'Sullivan TA, Morrison M, Jeffrey GP. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2020;40:1356-65. [PMID: 32243703 DOI: 10.1111/liv.14453] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
319 Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem. 2015;48:923-930. [PMID: 26151226 DOI: 10.1016/j.clinbiochem.2015.06.023] [Cited by in Crossref: 128] [Cited by in F6Publishing: 111] [Article Influence: 21.3] [Reference Citation Analysis]
320 Muriel P, López-Sánchez P, Ramos-Tovar E. Fructose and the Liver. Int J Mol Sci 2021;22:6969. [PMID: 34203484 DOI: 10.3390/ijms22136969] [Reference Citation Analysis]
321 Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16:377-386. [PMID: 31024089 DOI: 10.1038/s41575-019-0144-8] [Cited by in Crossref: 144] [Cited by in F6Publishing: 107] [Article Influence: 72.0] [Reference Citation Analysis]
322 Pandak WM, Kakiyama G. The acidic pathway of bile acid synthesis: Not just an alternative pathway. Liver Res 2019;3:88-98. [PMID: 32015930 DOI: 10.1016/j.livres.2019.05.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 16.0] [Reference Citation Analysis]
323 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Reference Citation Analysis]
324 de Sant'Ana LP, Ribeiro DJS, Martins AMA, Dos Santos FN, Corrêa R, Almeida RDN, Eberlin MN, Maurice CF, Magalhães KG. Absence of the Caspases 1/11 Modulates Liver Global Lipid Profile and Gut Microbiota in High-Fat-Diet-Induced Obese Mice. Front Immunol 2019;10:2926. [PMID: 31998283 DOI: 10.3389/fimmu.2019.02926] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
325 Miao Z, Cheng R, Zhang Y, Liang H, Jiang F, Shen X, Chen G, Zhang Q, He F, Li M. Antibiotics can cause weight loss by impairing gut microbiota in mice and the potent benefits of lactobacilli. Bioscience, Biotechnology, and Biochemistry 2020;84:411-20. [DOI: 10.1080/09168451.2019.1676696] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
326 Meroni M, Longo M, Rustichelli A, Dongiovanni P. Nutrition and Genetics in NAFLD: The Perfect Binomium. Int J Mol Sci 2020;21:E2986. [PMID: 32340286 DOI: 10.3390/ijms21082986] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
327 Baeg MK, Yoon SK, Ko SH, Noh YS, Lee IS, Choi MG. Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease. World J Gastroenterol 2016;22:2592-600. [PMID: 26937147 DOI: 10.3748/wjg.v22.i8.2592] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
328 Ju L, Sun Y, Xue H, Chen L, Gu C, Shao J, Lu R, Luo X, Wei J, Ma X, Bian Z. CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis. Sci Rep 2020;10:3201. [PMID: 32081971 DOI: 10.1038/s41598-020-60138-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
329 Dai X, Hou H, Zhang W, Liu T, Li Y, Wang S, Wang B, Cao H. Microbial Metabolites: Critical Regulators in NAFLD.Front Microbiol. 2020;11:567654. [PMID: 33117316 DOI: 10.3389/fmicb.2020.567654] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
330 Aragonès G, Colom-Pellicer M, Aguilar C, Guiu-Jurado E, Martínez S, Sabench F, Antonio Porras J, Riesco D, Del Castillo D, Richart C, Auguet T. Circulating microbiota-derived metabolites: a "liquid biopsy? Int J Obes (Lond) 2020;44:875-85. [PMID: 31388096 DOI: 10.1038/s41366-019-0430-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
331 Hendrikx T, Schnabl B. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. J Intern Med 2019;286:32-40. [PMID: 30873652 DOI: 10.1111/joim.12892] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 20.0] [Reference Citation Analysis]
332 Protopapas AA, Cholongitas E, Chrysavgis L, Tziomalos K. Alcohol consumption in patients with nonalcoholic fatty liver disease: yes, or no? Ann Gastroenterol 2021;34:476-86. [PMID: 34276185 DOI: 10.20524/aog.2021.0641] [Reference Citation Analysis]
333 De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, Mingarelli E, Facinelli B, Magi G, Palmieri C, Marzioni M, Benedetti A, Svegliati-Baroni G. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 2014;59:1738-1749. [PMID: 23959503 DOI: 10.1002/hep.26695] [Cited by in Crossref: 175] [Cited by in F6Publishing: 155] [Article Influence: 25.0] [Reference Citation Analysis]
334 Wang J, Chen WD, Wang YD. The Relationship Between Gut Microbiota and Inflammatory Diseases: The Role of Macrophages. Front Microbiol 2020;11:1065. [PMID: 32582063 DOI: 10.3389/fmicb.2020.01065] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
335 Ruuskanen MO, Åberg F, Männistö V, Havulinna AS, Méric G, Liu Y, Loomba R, Vázquez-Baeza Y, Tripathi A, Valsta LM, Inouye M, Jousilahti P, Salomaa V, Jain M, Knight R, Lahti L, Niiranen TJ. Links between gut microbiome composition and fatty liver disease in a large population sample. Gut Microbes 2021;13:1-22. [PMID: 33651661 DOI: 10.1080/19490976.2021.1888673] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
336 Noureddin M, Sanyal AJ. Pathogenesis of NASH: The Impact of Multiple Pathways. Curr Hepatol Rep 2018;17:350-60. [PMID: 31380156 DOI: 10.1007/s11901-018-0425-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 9.3] [Reference Citation Analysis]
337 Wankhade UD, Zhong Y, Kang P, Alfaro M, Chintapalli SV, Thakali KM, Shankar K. Enhanced offspring predisposition to steatohepatitis with maternal high-fat diet is associated with epigenetic and microbiome alterations. PLoS One 2017;12:e0175675. [PMID: 28414763 DOI: 10.1371/journal.pone.0175675] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 18.3] [Reference Citation Analysis]
338 Bieghs V, Trautwein C. Innate immune signaling and gut-liver interactions in non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2014;3:377-385. [PMID: 25568861 DOI: 10.3978/j.issn.2304-3881.2014.12.04] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
339 Tang W, Yao X, Xia F, Yang M, Chen Z, Zhou B, Liu Q. Modulation of the Gut Microbiota in Rats by Hugan Qingzhi Tablets during the Treatment of High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev 2018;2018:7261619. [PMID: 30671174 DOI: 10.1155/2018/7261619] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 12.3] [Reference Citation Analysis]
340 Haslam DB. Nonalcoholic steatohepatitis and the intestinal microbiota. Hepatology 2016;65:401-3. [DOI: 10.1002/hep.28864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
341 Mouzaki M, Wang AY, Bandsma R, Comelli EM, Arendt BM, Zhang L, Fung S, Fischer SE, McGilvray IG, Allard JP. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. PLoS One. 2016;11:e0151829. [PMID: 27203081 DOI: 10.1371/journal.pone.0151829] [Cited by in Crossref: 167] [Cited by in F6Publishing: 152] [Article Influence: 33.4] [Reference Citation Analysis]
342 Quesada-Vázquez S, Aragonès G, Del Bas JM, Escoté X. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis. Cells 2020;9:E176. [PMID: 31936799 DOI: 10.3390/cells9010176] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 19.0] [Reference Citation Analysis]
343 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3478/wjg.v20.i7.1712] [Reference Citation Analysis]
344 Lau LHS, Wong SH. Microbiota, Obesity and NAFLD. Adv Exp Med Biol. 2018;1061:111-125. [PMID: 29956210 DOI: 10.1007/978-981-10-8684-7_9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
345 Kurilshikov A, van den Munckhof ICL, Chen L, Bonder MJ, Schraa K, Rutten JHW, Riksen NP, de Graaf J, Oosting M, Sanna S, Joosten LAB, van der Graaf M, Brand T, Koonen DPY, van Faassen M, Slagboom PE, Xavier RJ, Kuipers F, Hofker MH, Wijmenga C, Netea MG, Zhernakova A, Fu J; LifeLines DEEP Cohort Study, BBMRI Metabolomics Consortium. Gut Microbial Associations to Plasma Metabolites Linked to Cardiovascular Phenotypes and Risk. Circ Res 2019;124:1808-20. [PMID: 30971183 DOI: 10.1161/CIRCRESAHA.118.314642] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 26.5] [Reference Citation Analysis]
346 Panasevich MR, Peppler WT, Oerther DB, Wright DC, Rector RS. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. Physiol Genomics. 2017;49:385-399. [PMID: 28600319 DOI: 10.1152/physiolgenomics.00012.2017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
347 Ji Y, Yin Y, Sun L, Zhang W. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement. Int J Mol Sci 2020;21:E3066. [PMID: 32357561 DOI: 10.3390/ijms21093066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
348 Dietert RR, Dietert JM. The Microbiome and Sustainable Healthcare. Healthcare (Basel) 2015;3:100-29. [PMID: 27417751 DOI: 10.3390/healthcare3010100] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
349 Ye J, Lv L, Wu W, Li Y, Shi D, Fang D, Guo F, Jiang H, Yan R, Ye W, Li L. Butyrate Protects Mice Against Methionine-Choline-Deficient Diet-Induced Non-alcoholic Steatohepatitis by Improving Gut Barrier Function, Attenuating Inflammation and Reducing Endotoxin Levels. Front Microbiol. 2018;9:1967. [PMID: 30186272 DOI: 10.3389/fmicb.2018.01967] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 22.7] [Reference Citation Analysis]
350 Keskitalo A, Munukka E, Toivonen R, Hollmén M, Kainulainen H, Huovinen P, Jalkanen S, Pekkala S. Enterobacter cloacae administration induces hepatic damage and subcutaneous fat accumulation in high-fat diet fed mice. PLoS One 2018;13:e0198262. [PMID: 29847581 DOI: 10.1371/journal.pone.0198262] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
351 Leylabadlo HE, Ghotaslou R, Feizabadi MM, Farajnia S, Moaddab SY, Ganbarov K, Khodadadi E, Tanomand A, Sheykhsaran E, Yousefi B, Kafil HS. The critical role of Faecalibacterium prausnitzii in human health: An overview. Microb Pathog 2020;149:104344. [PMID: 32534182 DOI: 10.1016/j.micpath.2020.104344] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 17.0] [Reference Citation Analysis]
352 Putignani L, Del Chierico F, Petrucca A, Vernocchi P, Dallapiccola B. The human gut microbiota: a dynamic interplay with the host from birth to senescence settled during childhood. Pediatr Res. 2014;76:2-10. [PMID: 24732106 DOI: 10.1038/pr.2014.49] [Cited by in Crossref: 121] [Cited by in F6Publishing: 99] [Article Influence: 17.3] [Reference Citation Analysis]
353 Wahlang B, Alexander NC 2nd, Li X, Rouchka EC, Kirpich IA, Cave MC. Polychlorinated biphenyls altered gut microbiome in CAR and PXR knockout mice exhibiting toxicant-associated steatohepatitis. Toxicol Rep 2021;8:536-47. [PMID: 33777700 DOI: 10.1016/j.toxrep.2021.03.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
354 Kim H, Worsley O, Yang E, Purbojati RW, Liang AL, Tan W, Moses DID, Hartono S, Fan V, Lim TKH, Schuster SC, Foo RS, Chow PKH, Pettersson S. Persistent changes in liver methylation and microbiome composition following reversal of diet-induced non-alcoholic-fatty liver disease. Cell Mol Life Sci 2019;76:4341-54. [PMID: 31119300 DOI: 10.1007/s00018-019-03114-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
355 Zhang S, Zhao J, Xie F, He H, Johnston LJ, Dai X, Wu C, Ma X. Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease. Obes Rev 2021;:e13316. [PMID: 34279051 DOI: 10.1111/obr.13316] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
356 Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Childs CE, Del Fabbro S, Bilson J, Moyses HE, Clough GF, Sethi JK, Patel J, Wright M, Breen DJ, Peebles C, Darekar A, Aspinall R, Fowell AJ, Dowman JK, Nobili V, Targher G, Delzenne NM, Bindels LB, Calder PC, Byrne CD. Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology. 2020;158:1597-1610. [PMID: 31987796 DOI: 10.1053/j.gastro.2020.01.031] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 38.0] [Reference Citation Analysis]
357 Yu Q, Wu L, Ji J, Feng J, Dai W, Li J, Wu J, Guo C. Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma. J Hepatocell Carcinoma 2020;7:271-88. [PMID: 33150145 DOI: 10.2147/JHC.S277870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
358 Kessoku T, Imajo K, Kobayashi T, Ozaki A, Iwaki M, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol 2020;5:996-1007. [PMID: 32805205 DOI: 10.1016/S2468-1253(20)30216-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
359 Aljomah G, Baker SS, Liu W, Kozielski R, Oluwole J, Lupu B, Baker RD, Zhu L. Induction of CYP2E1 in non-alcoholic fatty liver diseases. Exp Mol Pathol 2015;99:677-81. [PMID: 26551085 DOI: 10.1016/j.yexmp.2015.11.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
360 Li DY, Yang M, Edwards S, Ye SQ. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota? JPEN J Parenter Enteral Nutr. 2013;37:787-793. [PMID: 23538296 DOI: 10.1177/0148607113481623] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
361 Chen X, Li HY, Hu XM, Zhang Y, Zhang SY. Current understanding of gut microbiota alterations and related therapeutic intervention strategies in heart failure. Chin Med J (Engl) 2019;132:1843-55. [PMID: 31306229 DOI: 10.1097/CM9.0000000000000330] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
362 Takakura K, Oikawa T, Nakano M, Saeki C, Torisu Y, Kajihara M, Saruta M. Recent Insights Into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma.Front Oncol. 2019;9:762. [PMID: 31456946 DOI: 10.3389/fonc.2019.00762] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
363 Mima K, Nakagawa S, Sawayama H, Ishimoto T, Imai K, Iwatsuki M, Hashimoto D, Baba Y, Yamashita YI, Yoshida N, Chikamoto A, Baba H. The microbiome and hepatobiliary-pancreatic cancers.Cancer Lett. 2017;402:9-15. [PMID: 28527946 DOI: 10.1016/j.canlet.2017.05.001] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 14.3] [Reference Citation Analysis]
364 Murata C, Gutiérrez-Castrellón P, Pérez-Villatoro F, García-Torres I, Enríquez-Flores S, de la Mora-de la Mora I, Fernández-Lainez C, Werner J, López-Velázquez G. Delivery mode-associated gut microbiota in the first 3 months of life in a country with high obesity rates: A descriptive study. Medicine (Baltimore) 2020;99:e22442. [PMID: 33019428 DOI: 10.1097/MD.0000000000022442] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
365 Pose E, Pera G, Torán P, Gratacós-Ginès J, Avitabile E, Expósito C, Díaz A, Graupera I, Rubio AB, Ginès P, Fabrellas N, Caballeria L. Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population-based study. Liver Int 2021;41:1556-64. [PMID: 33595176 DOI: 10.1111/liv.14830] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
366 Jiao N, Loomba R, Yang ZH, Wu D, Fang S, Bettencourt R, Lan P, Zhu R, Zhu L. Alterations in bile acid metabolizing gut microbiota and specific bile acid genes as a precision medicine to subclassify NAFLD. Physiol Genomics 2021;53:336-48. [PMID: 34151600 DOI: 10.1152/physiolgenomics.00011.2021] [Reference Citation Analysis]
367 Fei N, Bruneau A, Zhang X, Wang R, Wang J, Rabot S, Gérard P, Zhao L. Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease. mBio 2020;11:e03263-19. [PMID: 32019793 DOI: 10.1128/mBio.03263-19] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 23.0] [Reference Citation Analysis]
368 Gao Y, Zhang J, Xiao X, Ren Y, Yan X, Yue J, Wang T, Wu Z, Lv Y, Wu R. The Role of Gut Microbiota in Duodenal-Jejunal Bypass Surgery-Induced Improvement of Hepatic Steatosis in HFD-Fed Rats. Front Cell Infect Microbiol 2021;11:640448. [PMID: 33869077 DOI: 10.3389/fcimb.2021.640448] [Reference Citation Analysis]
369 Wang B, Wang L, Wang H, Dai H, Lu X, Lee YK, Gu Z, Zhao J, Zhang H, Chen W, Wang G. Targeting the Gut Microbiota for Remediating Obesity and Related Metabolic Disorders. J Nutr 2021;151:1703-16. [PMID: 33982127 DOI: 10.1093/jn/nxab103] [Reference Citation Analysis]
370 Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K. Outcomes of Japanese patients with non-alcoholic fatty liver disease according to genetic background and lifestyle-related diseases. Ann Hepatol 2021;21:100260. [PMID: 32987175 DOI: 10.1016/j.aohep.2020.09.004] [Reference Citation Analysis]
371 Dong TS, Luu K, Lagishetty V, Sedighian F, Woo SL, Dreskin BW, Katzka W, Chang C, Zhou Y, Arias-Jayo N, Yang J, Ahdoot AI, Ye J, Li Z, Pisegna JR, Jacobs JP. The Intestinal Microbiome Predicts Weight Loss on a Calorie-Restricted Diet and Is Associated With Improved Hepatic Steatosis. Front Nutr 2021;8:718661. [PMID: 34307440 DOI: 10.3389/fnut.2021.718661] [Reference Citation Analysis]
372 Pham TP, Tidjani Alou M, Bachar D, Levasseur A, Brah S, Alhousseini D, Sokhna C, Diallo A, Wieringa F, Million M, Raoult D. Gut Microbiota Alteration is Characterized by a Proteobacteria and Fusobacteria Bloom in Kwashiorkor and a Bacteroidetes Paucity in Marasmus. Sci Rep 2019;9:9084. [PMID: 31235833 DOI: 10.1038/s41598-019-45611-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
373 Liang Y, Zhang Y, Deng Y, Liang S, He Y, Chen Y, Liu C, Lin C, Han L, Tu G, Yang Q. Chaihu-Shugan-San Decoction Modulates Intestinal Microbe Dysbiosis and Alleviates Chronic Metabolic Inflammation in NAFLD Rats via the NLRP3 Inflammasome Pathway. Evid Based Complement Alternat Med 2018;2018:9390786. [PMID: 30105078 DOI: 10.1155/2018/9390786] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
374 Albhaisi SAM, Bajaj JS. The Influence of the Microbiome on NAFLD and NASH. Clin Liver Dis (Hoboken) 2021;17:15-8. [PMID: 33552480 DOI: 10.1002/cld.1010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
375 Delzenne NM, Knudsen C, Beaumont M, Rodriguez J, Neyrinck AM, Bindels LB. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut–liver axis. Proc Nutr Soc 2019;78:319-28. [DOI: 10.1017/s0029665118002756] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 17.5] [Reference Citation Analysis]
376 Lensu S, Pariyani R, Mäkinen E, Yang B, Saleem W, Munukka E, Lehti M, Driuchina A, Lindén J, Tiirola M, Lahti L, Pekkala S. Prebiotic Xylo-Oligosaccharides Ameliorate High-Fat-Diet-Induced Hepatic Steatosis in Rats. Nutrients 2020;12:E3225. [PMID: 33105554 DOI: 10.3390/nu12113225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
377 Choo JM, Leong LE, Rogers GB. Sample storage conditions significantly influence faecal microbiome profiles. Sci Rep 2015;5:16350. [PMID: 26572876 DOI: 10.1038/srep16350] [Cited by in Crossref: 217] [Cited by in F6Publishing: 191] [Article Influence: 36.2] [Reference Citation Analysis]
378 Hatton G, Alterio T, Nobili V, Mann JP. Unmet needs in pediatric NAFLD research: what do we need to prioritize for the future? Expert Review of Gastroenterology & Hepatology 2018;12:961-7. [DOI: 10.1080/17474124.2018.1512853] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
379 Da Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, Lou W, Allard JP. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep. 2018;8:1466. [PMID: 29362454 DOI: 10.1038/s41598-018-19753-9] [Cited by in Crossref: 102] [Cited by in F6Publishing: 91] [Article Influence: 34.0] [Reference Citation Analysis]
380 Yun Y, Kim HN, Lee EJ, Ryu S, Chang Y, Shin H, Kim HL, Kim TH, Yoo K, Kim HY. Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese vs lean subjects. PLoS One. 2019;14:e0213692. [PMID: 30870486 DOI: 10.1371/journal.pone.0213692] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 13.0] [Reference Citation Analysis]
381 Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, Thomas LV, Zoetendal EG, Hart A. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65:330-339. [PMID: 26338727 DOI: 10.1136/gutjnl-2015-309990] [Cited by in Crossref: 997] [Cited by in F6Publishing: 791] [Article Influence: 166.2] [Reference Citation Analysis]
382 Camilleri M. What is the leaky gut? Clinical considerations in humans. Curr Opin Clin Nutr Metab Care 2021;24:473-82. [PMID: 34138767 DOI: 10.1097/MCO.0000000000000778] [Reference Citation Analysis]
383 Zhang X, Coker OO, Chu ES, Fu K, Lau HCH, Wang YX, Chan AWH, Wei H, Yang X, Sung JJY, Yu J. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut 2021;70:761-74. [PMID: 32694178 DOI: 10.1136/gutjnl-2019-319664] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 28.0] [Reference Citation Analysis]
384 Sharpton SR, Yong GJM, Terrault NA, Lynch SV. Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease. Hepatol Commun 2019;3:29-43. [PMID: 30619992 DOI: 10.1002/hep4.1284] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
385 Carvalho DV, Silva LMA, Alves Filho EG, Santos FA, Lima RP, Viana AFSC, Nunes PIG, Fonseca SGDC, Melo TS, Viana DA, Gallão MI, Brito ES. Cashew apple fiber prevents high fat diet-induced obesity in mice: an NMR metabolomic evaluation. Food Funct 2019;10:1671-83. [PMID: 30839972 DOI: 10.1039/c8fo01575a] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 4.5] [Reference Citation Analysis]
386 Chen YH, Wu WK, Wu MS. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. Int J Mol Sci 2020;21:E5999. [PMID: 32825440 DOI: 10.3390/ijms21175999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
387 Harvie R, Chanyi RM, Burton JP, Schultz M. Using the Human Gastrointestinal Microbiome to Personalize Nutrition Advice: Are Registered Dietitian Nutritionists Ready for the Opportunities and Challenges? J Acad Nutr Diet. 2016; Epub ahead of print. [PMID: 27986518 DOI: 10.1016/j.jand.2016.10.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
388 Sohn W, Jun DW, Lee KN, Lee HL, Lee OY, Choi HS, Yoon BC. Lactobacillus paracasei Induces M2-Dominant Kupffer Cell Polarization in a Mouse Model of Nonalcoholic Steatohepatitis. Dig Dis Sci 2015;60:3340-50. [PMID: 26143342 DOI: 10.1007/s10620-015-3770-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
389 Younossi ZM, Karrar A, Pierobon M, Birerdinc A, Stepanova M, Abdelatif D, Younoszai Z, Jeffers T, Felix S, Jeiran K, Hodge A, Zhou W, Monge F, Alaparthi L, Chandhoke V, Goodman ZD, Petricoin EF. An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease. BMC Med 2018;16:170. [PMID: 30205811 DOI: 10.1186/s12916-018-1136-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
390 Jain T, Sharma P, Are AC, Vickers SM, Dudeja V. New Insights Into the Cancer-Microbiome-Immune Axis: Decrypting a Decade of Discoveries. Front Immunol 2021;12:622064. [PMID: 33708214 DOI: 10.3389/fimmu.2021.622064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
391 Chen K, Ma J, Jia X, Ai W, Ma Z, Pan Q. Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans. Biochim Biophys Acta Rev Cancer. 2019;1871:117-125. [PMID: 30528647 DOI: 10.1016/j.bbcan.2018.11.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
392 Sivaraj S, Chan A, Pasini E, Chen E, Lawendy B, Verna E, Watt K, Bhat M. Enteric dysbiosis in liver and kidney transplant recipients: a systematic review. Transpl Int 2020;33:1163-76. [PMID: 32640109 DOI: 10.1111/tri.13696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
393 Peluso I, Manafikhi H, Reggi R, Palmery M. Effects of red wine on postprandial stress: potential implication in non-alcoholic fatty liver disease development. Eur J Nutr. 2015;54:497-507. [PMID: 25772634 DOI: 10.1007/s00394-015-0877-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
394 Hui ST, Parks BW, Org E, Norheim F, Che N, Pan C, Castellani LW, Charugundla S, Dirks DL, Psychogios N, Neuhaus I, Gerszten RE, Kirchgessner T, Gargalovic PS, Lusis AJ. The genetic architecture of NAFLD among inbred strains of mice. Elife 2015;4:e05607. [PMID: 26067236 DOI: 10.7554/eLife.05607] [Cited by in Crossref: 58] [Cited by in F6Publishing: 39] [Article Influence: 9.7] [Reference Citation Analysis]
395 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
396 Nawrot M, Peschard S, Lestavel S, Staels B. Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. Metabolism 2021;123:154844. [PMID: 34343577 DOI: 10.1016/j.metabol.2021.154844] [Reference Citation Analysis]
397 Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019;15:261-273. [PMID: 30670819 DOI: 10.1038/s41574-019-0156-z] [Cited by in Crossref: 288] [Cited by in F6Publishing: 233] [Article Influence: 144.0] [Reference Citation Analysis]
398 De Angelis M, Garruti G, Minervini F, Bonfrate L, Portincasa P, Gobbetti M. The Food-gut Human Axis: The Effects of Diet on Gut Microbiota and Metabolome. Curr Med Chem. 2019;26:3567-3583. [PMID: 28462705 DOI: 10.2174/0929867324666170428103848] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 14.0] [Reference Citation Analysis]
399 Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, Federico A, Persico M. Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev 2018;2018:9547613. [PMID: 29991976 DOI: 10.1155/2018/9547613] [Cited by in Crossref: 205] [Cited by in F6Publishing: 178] [Article Influence: 68.3] [Reference Citation Analysis]
400 Sharpton SR, Maraj B, Harding-Theobald E, Vittinghoff E, Terrault NA. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr 2019;110:139-49. [PMID: 31124558 DOI: 10.1093/ajcn/nqz042] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 32.0] [Reference Citation Analysis]
401 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839] [Reference Citation Analysis]
402 Miloh T. Probiotics in Pediatric Liver Disease. J Clin Gastroenterol 2015;49 Suppl 1:S33-6. [PMID: 26447962 DOI: 10.1097/MCG.0000000000000365] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
403 Li X, Liang S, Xia Z, Qu J, Liu H, Liu C, Yang H, Wang J, Madsen L, Hou Y, Li J, Jia H, Kristiansen K, Xiao L. Establishment of a Macaca fascicularis gut microbiome gene catalog and comparison with the human, pig, and mouse gut microbiomes. Gigascience 2018;7. [PMID: 30137359 DOI: 10.1093/gigascience/giy100] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
404 Watanabe K, Katagiri S, Takahashi H, Sasaki N, Maekawa S, Komazaki R, Hatasa M, Kitajima Y, Maruyama Y, Shiba T, Komatsu K, Ohsugi Y, Tanaka K, Matsuzawa A, Hirota T, Tohara H, Eguchi Y, Anzai K, Hattori A, Iwata T. Porphyromonas gingivalis impairs glucose uptake in skeletal muscle associated with altering gut microbiota. FASEB j 2021;35. [DOI: 10.1096/fj.202001158r] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
405 Jasirwan COM, Muradi A, Hasan I, Simadibrata M, Rinaldi I. Correlation of gut Firmicutes/Bacteroidetes ratio with fibrosis and steatosis stratified by body mass index in patients with non-alcoholic fatty liver disease. Biosci Microbiota Food Health 2021;40:50-8. [PMID: 33520569 DOI: 10.12938/bmfh.2020-046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
406 Dong X, Feng X, Liu J, Xu Y, Pan Q, Ling Z, Yu J, Yang J, Li L, Cao H. Characteristics of Intestinal Microecology during Mesenchymal Stem Cell-Based Therapy for Mouse Acute Liver Injury. Stem Cells Int 2019;2019:2403793. [PMID: 30867666 DOI: 10.1155/2019/2403793] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
407 Chu H, Duan Y, Yang L, Schnabl B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut. 2019;68:359-370. [PMID: 30171065 DOI: 10.1136/gutjnl-2018-316307] [Cited by in Crossref: 115] [Cited by in F6Publishing: 100] [Article Influence: 38.3] [Reference Citation Analysis]
408 Tian Y, Wang H, Yuan F, Li N, Huang Q, He L, Wang L, Liu Z. Perilla Oil Has Similar Protective Effects of Fish Oil on High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease and Gut Dysbiosis. Biomed Res Int 2016;2016:9462571. [PMID: 27051672 DOI: 10.1155/2016/9462571] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
409 Neuman MG, French SW, Zakhari S, Malnick S, Seitz HK, Cohen LB, Salaspuro M, Voinea-Griffin A, Barasch A, Kirpich IA, Thomes PG, Schrum LW, Donohue TM Jr, Kharbanda KK, Cruz M, Opris M. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. Exp Mol Pathol 2017;102:162-80. [PMID: 28077318 DOI: 10.1016/j.yexmp.2017.01.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
410 Jadhav K, Cohen TS. Can You Trust Your Gut? Front Endocrinol (Lausanne). 2020;11:592157. [PMID: 33193105 DOI: 10.3389/fendo.2020.592157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
411 Aktas B, De Wolfe TJ, Tandee K, Safdar N, Darien BJ, Steele JL. The Effect of Lactobacillus casei 32G on the Mouse Cecum Microbiota and Innate Immune Response Is Dose and Time Dependent. PLoS One 2015;10:e0145784. [PMID: 26714177 DOI: 10.1371/journal.pone.0145784] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
412 Maricic I, Marrero I, Eguchi A, Nakamura R, Johnson CD, Dasgupta S, Hernandez CD, Nguyen PS, Swafford AD, Knight R, Feldstein AE, Loomba R, Kumar V. Differential Activation of Hepatic Invariant NKT Cell Subsets Plays a Key Role in Progression of Nonalcoholic Steatohepatitis. J Immunol 2018;201:3017-35. [PMID: 30322964 DOI: 10.4049/jimmunol.1800614] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
413 Brandl K, Schnabl B. Intestinal microbiota and nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2017;33:128-33. [PMID: 28257306 DOI: 10.1097/MOG.0000000000000349] [Cited by in Crossref: 70] [Cited by in F6Publishing: 33] [Article Influence: 17.5] [Reference Citation Analysis]
414 Haque TR, Barritt AS. Intestinal microbiota in liver disease. Best Practice & Research Clinical Gastroenterology 2016;30:133-42. [DOI: 10.1016/j.bpg.2016.02.004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 8.2] [Reference Citation Analysis]
415 Manzhalii E, Virchenko O, Falalyeyeva T, Beregova T, Stremmel W. Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: A pilot trial. J Dig Dis 2017;18:698-703. [PMID: 29148175 DOI: 10.1111/1751-2980.12561] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
416 Ma J, Li H. The Role of Gut Microbiota in Atherosclerosis and Hypertension. Front Pharmacol 2018;9:1082. [PMID: 30319417 DOI: 10.3389/fphar.2018.01082] [Cited by in Crossref: 92] [Cited by in F6Publishing: 70] [Article Influence: 30.7] [Reference Citation Analysis]
417 Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72:785-801. [PMID: 32059982 DOI: 10.1016/j.jhep.2020.01.013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 56.0] [Reference Citation Analysis]
418 Chu H, Williams B, Schnabl B. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Liver Res. 2018;2:43-51. [PMID: 30416839 DOI: 10.1016/j.livres.2017.11.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
419 Kang K, Sun Y, Pan D, Sang LX, Sun MJ, Li YL, Chang B. Distinctive gut microbial dysbiosis between chronic alcoholic fatty liver disease and metabolic-associated fatty liver disease in mice. Exp Ther Med 2021;21:418. [PMID: 33777186 DOI: 10.3892/etm.2021.9862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
420 Wang WL, Xu SY, Ren ZG, Tao L, Jiang JW, Zheng SS. Application of metagenomics in the human gut microbiome. World J Gastroenterol 2015;21:803-14. [PMID: 25624713 DOI: 10.3748/wjg.v21.i3.803] [Cited by in CrossRef: 164] [Cited by in F6Publishing: 110] [Article Influence: 27.3] [Reference Citation Analysis]
421 Panasevich MR, Meers GM, Linden MA, Booth FW, Perfield JW 2nd, Fritsche KL, Wankhade UD, Chintapalli SV, Shankar K, Ibdah JA, Rector RS. High-fat, high-fructose, high-cholesterol feeding causes severe NASH and cecal microbiota dysbiosis in juvenile Ossabaw swine. Am J Physiol Endocrinol Metab 2018;314:E78-92. [PMID: 28899857 DOI: 10.1152/ajpendo.00015.2017] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
422 Taniguchi H, Tanisawa K, Sun X, Kubo T, Hoshino Y, Hosokawa M, Takeyama H, Higuchi M. Effects of short-term endurance exercise on gut microbiota in elderly men. Physiol Rep. 2018;6:e13935. [PMID: 30536648 DOI: 10.14814/phy2.13935] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
423 Houttu V, Csader S, Nieuwdorp M, Holleboom AG, Schwab U. Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Nutr 2021;8:716783. [PMID: 34368214 DOI: 10.3389/fnut.2021.716783] [Reference Citation Analysis]
424 Mann JP, Raponi M, Nobili V. Clinical implications of understanding the association between oxidative stress and pediatric NAFLD. Expert Rev Gastroenterol Hepatol. 2017;11:371-382. [PMID: 28162008 DOI: 10.1080/17474124.2017.1291340] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 5.8] [Reference Citation Analysis]
425 Engelstad HJ, Barron L, Moen J, Wylie TN, Wylie K, Rubin DC, Davidson N, Cade WT, Warner BB, Warner BW. Remnant Small Bowel Length in Pediatric Short Bowel Syndrome and the Correlation with Intestinal Dysbiosis and Linear Growth. J Am Coll Surg 2018;227:439-49. [PMID: 30077861 DOI: 10.1016/j.jamcollsurg.2018.07.657] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
426 Boeckmans J, Natale A, Buyl K, Rogiers V, De Kock J, Vanhaecke T, Rodrigues RM. Human-based systems: Mechanistic NASH modelling just around the corner? Pharmacol Res 2018;134:257-67. [PMID: 29964161 DOI: 10.1016/j.phrs.2018.06.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
427 Sobhonslidsuk A, Chanprasertyothin S, Pongrujikorn T, Kaewduang P, Promson K, Petraksa S, Ongphiphadhanakul B. The Association of Gut Microbiota with Nonalcoholic Steatohepatitis in Thais. Biomed Res Int 2018;2018:9340316. [PMID: 29682571 DOI: 10.1155/2018/9340316] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
428 Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120-127. [PMID: 23401313 DOI: 10.1002/hep.26319] [Cited by in Crossref: 401] [Cited by in F6Publishing: 350] [Article Influence: 50.1] [Reference Citation Analysis]
429 Shen F, Zheng RD, Sun XQ, Ding WJ, Wang XY, Fan JG. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2017;16:375-381. [PMID: 28823367 DOI: 10.1016/s1499-3872(17)60019-5] [Cited by in Crossref: 144] [Cited by in F6Publishing: 74] [Article Influence: 48.0] [Reference Citation Analysis]
430 Gröschel C, Prinz-Wohlgenannt M, Mesteri I, Karuthedom George S, Trawnicek L, Heiden D, Aggarwal A, Tennakoon S, Baumgartner M, Gasche C, Lang M, Marculescu R, Manhardt T, Schepelmann M, Kallay E. Switching to a Healthy Diet Prevents the Detrimental Effects of Western Diet in a Colitis-Associated Colorectal Cancer Model. Nutrients 2019;12:E45. [PMID: 31877961 DOI: 10.3390/nu12010045] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
431 Rajesh Y, Sarkar D. Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1290. [PMID: 32443737 DOI: 10.3390/cancers12051290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
432 Muscogiuri G, Cantone E, Cassarano S, Tuccinardi D, Barrea L, Savastano S, Colao A; on behalf of the Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group. Gut microbiota: a new path to treat obesity. Int J Obes Suppl 2019;9:10-9. [PMID: 31391921 DOI: 10.1038/s41367-019-0011-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 53] [Article Influence: 36.0] [Reference Citation Analysis]
433 Smith K. Microbiota: Gut microbiota produce alcohol in patients with NASH. Nat Rev Gastroenterol Hepatol 2012;9:687. [PMID: 23147655 DOI: 10.1038/nrgastro.2012.209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
434 Abdou RM, Zhu L, Baker RD, Baker SS. Gut Microbiota of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1268-1281. [PMID: 26898658 DOI: 10.1007/s10620-016-4045-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 7.4] [Reference Citation Analysis]
435 He Z, Ding R, Wu F, Wu Z, Liang C. Excess Alcohol Consumption: A Potential Mechanism Behind the Association Between Small Intestinal Bacterial Overgrowth and Coronary Artery Disease. Dig Dis Sci 2018;63:3516-7. [PMID: 30367306 DOI: 10.1007/s10620-018-5279-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
436 Arab JP, Arrese M, Shah VH. Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives. Hepatol Res 2020;50:407-18. [PMID: 31840358 DOI: 10.1111/hepr.13473] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
437 Cozzolino R, De Giulio B, Marena P, Martignetti A, Günther K, Lauria F, Russo P, Stocchero M, Siani A. Urinary volatile organic compounds in overweight compared to normal-weight children: results from the Italian I.Family cohort. Sci Rep 2017;7:15636. [PMID: 29142292 DOI: 10.1038/s41598-017-15957-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
438 Romeo S, Sanyal A, Valenti L. Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease. Cell Metabolism 2020;31:35-45. [DOI: 10.1016/j.cmet.2019.12.002] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 53.0] [Reference Citation Analysis]
439 Xie K, He X, Chen K, Sakao K, Hou DX. Ameliorative effects and molecular mechanisms of vine tea on western diet-induced NAFLD. Food Funct 2020;11:5976-91. [PMID: 32666969 DOI: 10.1039/d0fo00795a] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
440 Yuan J, Baker SS, Liu W, Alkhouri R, Baker RD, Xie J, Ji G, Zhu L. Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2014;29:1292-1298. [PMID: 24372861 DOI: 10.1111/jgh.12510] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 7.1] [Reference Citation Analysis]
441 Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146:1513-1524. [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020] [Cited by in Crossref: 487] [Cited by in F6Publishing: 426] [Article Influence: 69.6] [Reference Citation Analysis]
442 Adams LA, Morrison M. The Microbiome in Obesity, Diabetes, and NAFLD: What is Your Gut Telling Us? Curr Hepatology Rep 2016;15:96-102. [DOI: 10.1007/s11901-016-0299-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
443 Alvarez-Silva C, Schierwagen R, Pohlmann A, Magdaleno F, Uschner FE, Ryan P, Vehreschild MJGT, Claria J, Latz E, Lelouvier B, Arumugam M, Trebicka J. Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis. Front Immunol 2019;10:69. [PMID: 30800122 DOI: 10.3389/fimmu.2019.00069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
444 Shrestha R, Shrestha R, Qin XY, Kuo TF, Oshima Y, Iwatani S, Teraoka R, Fujii K, Hara M, Li M, Takahashi-Nakaguchi A, Chibana H, Lu J, Cai M, Kajiwara S, Kojima S. Fungus-derived hydroxyl radicals kill hepatic cells by enhancing nuclear transglutaminase. Sci Rep 2017;7:4746. [PMID: 28684792 DOI: 10.1038/s41598-017-04630-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
445 Lanthier N, Rodriguez J, Nachit M, Hiel S, Trefois P, Neyrinck AM, Cani PD, Bindels LB, Thissen JP, Delzenne NM. Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients. Sci Rep 2021;11:659. [PMID: 33436764 DOI: 10.1038/s41598-020-79718-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
446 Holterman A, Gurria J, Tanpure S, Disomma N. Nonalcoholic fatty liver disease and bariatric surgery in adolescents. Seminars in Pediatric Surgery 2014;23:49-57. [DOI: 10.1053/j.sempedsurg.2013.10.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
447 Zhu F, Li YM, Feng TT, Wu Y, Zhang HX, Jin GY, Liu JP. Freeze-dried Si-Ni-San powder can ameliorate high fat diet-induced non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25:3056-3068. [PMID: 31293341 DOI: 10.3748/wjg.v25.i24.3056] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
448 Sookoian S, Salatino A, Castaño GO, Landa MS, Fijalkowky C, Garaycoechea M, Pirola CJ. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. Gut 2020;69:1483-91. [DOI: 10.1136/gutjnl-2019-318811] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 35.0] [Reference Citation Analysis]
449 Fu ZD, Cui JY. Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites. Curr Pharmacol Rep 2017;3:101-13. [PMID: 28983453 DOI: 10.1007/s40495-017-0087-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
450 Philips CA, Phadke N, Ganesan K, Ranade S, Augustine P. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis. Indian J Gastroenterol. 2018;37:215-225. [PMID: 29931479 DOI: 10.1007/s12664-018-0859-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
451 Carotti S, Guarino MP, Vespasiani-Gentilucci U, Morini S. Starring role of toll-like receptor-4 activation in the gut-liver axis. World J Gastrointest Pathophysiol. 2015;6:99-109. [PMID: 26600967 DOI: 10.4291/wjgp.v6.i4.99] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
452 de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57:861-876. [PMID: 28875318 DOI: 10.1007/s00394-017-1524-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 10.8] [Reference Citation Analysis]
453 Fukui H. Gut Microbiota and Host Reaction in Liver Diseases. Microorganisms. 2015;3:759-791. [PMID: 27682116 DOI: 10.3390/microorganisms3040759] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
454 Guo Y, Ding PH, Liu LJ, Shi L, Mao TY, Li JX, Wang YL. Gegen Qinlian Decoction Attenuates High-Fat Diet-Induced Steatohepatitis in Rats via Gut Microbiota. Evid Based Complement Alternat Med 2018;2018:7370891. [PMID: 30671129 DOI: 10.1155/2018/7370891] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
455 Giles DA, Moreno-Fernandez ME, Stankiewicz TE, Graspeuntner S, Cappelletti M, Wu D, Mukherjee R, Chan CC, Lawson MJ, Klarquist J, Sünderhauf A, Softic S, Kahn CR, Stemmer K, Iwakura Y, Aronow BJ, Karns R, Steinbrecher KA, Karp CL, Sheridan R, Shanmukhappa SK, Reynaud D, Haslam DB, Sina C, Rupp J, Hogan SP, Divanovic S. Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling. Nat Med 2017;23:829-38. [PMID: 28604704 DOI: 10.1038/nm.4346] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 23.5] [Reference Citation Analysis]
456 Namasivayam S, Diarra B, Diabate S, Sarro YDS, Kone A, Kone B, Tolofoudie M, Baya B, Diakite MT, Kodio O, Cohen K, Holl J, Achenbach CJ, Chatterjee S, Murphy RL, Bishai W, Diallo S, Sher A, Maiga M. Patients infected with Mycobacterium africanum versus Mycobacterium tuberculosis possess distinct intestinal microbiota. PLoS Negl Trop Dis 2020;14:e0008230. [PMID: 32401750 DOI: 10.1371/journal.pntd.0008230] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
457 Matsumoto K, Ichimura M, Tsuneyama K, Moritoki Y, Tsunashima H, Omagari K, Hara M, Yasuda I, Miyakawa H, Kikuchi K. Fructo-oligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis. PLoS One 2017;12:e0175406. [PMID: 28632732 DOI: 10.1371/journal.pone.0175406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
458 Zhu L, Baker RD, Zhu R, Baker SS. Gut microbiota produce alcohol and contribute to NAFLD. Gut. 2016;65:1232. [PMID: 26984853 DOI: 10.1136/gutjnl-2016-311571] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
459 Campo L, Eiseler S, Apfel T, Pyrsopoulos N. Fatty Liver Disease and Gut Microbiota: A Comprehensive Update. J Clin Transl Hepatol. 2019;7:56-60. [PMID: 30944821 DOI: 10.14218/jcth.2018.00008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 6.3] [Reference Citation Analysis]
460 Kim HN, Joo EJ, Cheong HS, Kim Y, Kim HL, Shin H, Chang Y, Ryu S. Gut Microbiota and Risk of Persistent Nonalcoholic Fatty Liver Diseases. J Clin Med 2019;8:E1089. [PMID: 31344854 DOI: 10.3390/jcm8081089] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
461 Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B, Reo NV. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015;91:1-9. [PMID: 25764541 DOI: 10.1093/femsec/fiu002] [Cited by in Crossref: 136] [Cited by in F6Publishing: 116] [Article Influence: 19.4] [Reference Citation Analysis]
462 Tanwar S, Rhodes F, Srivastava A, Trembling PM, Rosenberg WM. Inflammation and fibrosis in chronic liver diseases including non-alcoholic fatty liver disease and hepatitis C. World J Gastroenterol 2020;26:109-33. [PMID: 31969775 DOI: 10.3748/wjg.v26.i2.109] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
463 Panasevich MR, Morris EM, Chintapalli SV, Wankhade UD, Shankar K, Britton SL, Koch LG, Thyfault JP, Rector RS. Gut microbiota are linked to increased susceptibility to hepatic steatosis in low-aerobic-capacity rats fed an acute high-fat diet. Am J Physiol Gastrointest Liver Physiol 2016;311:G166-79. [PMID: 27288420 DOI: 10.1152/ajpgi.00065.2016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
464 Houghton D, Stewart CJ, Day CP, Trenell M. Gut Microbiota and Lifestyle Interventions in NAFLD. Int J Mol Sci. 2016;17:447. [PMID: 27023533 DOI: 10.3390/ijms17040447] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
465 Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017;14:527-39. [PMID: 28676707 DOI: 10.1038/nrgastro.2017.72] [Cited by in Crossref: 176] [Cited by in F6Publishing: 148] [Article Influence: 44.0] [Reference Citation Analysis]
466 Atarashi M, Izawa T, Miyagi R, Ohji S, Hashimoto A, Kuwamura M, Yamate J. Dietary Iron Supplementation Alters Hepatic Inflammation in a Rat Model of Nonalcoholic Steatohepatitis. Nutrients 2018;10:E175. [PMID: 29401710 DOI: 10.3390/nu10020175] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
467 Anjani K, Lhomme M, Sokolovska N, Poitou C, Aron-Wisnewsky J, Bouillot JL, Lesnik P, Bedossa P, Kontush A, Clement K, Dugail I, Tordjman J. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. J Hepatol. 2015;62:905-912. [PMID: 25450212 DOI: 10.1016/j.jhep.2014.11.002] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]
468 Hendrikx T, Schnabl B. Antimicrobial proteins: intestinal guards to protect against liver disease. J Gastroenterol 2019;54:209-17. [PMID: 30392013 DOI: 10.1007/s00535-018-1521-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
469 Guohong-liu, Qingxi-zhao, Hongyun-wei. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis. Annals of Hepatology 2019;18:796-803. [DOI: 10.1016/j.aohep.2019.06.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
470 Hoedt EC, Cuív PÓ, Evans PN, Smith WJ, McSweeney CS, Denman SE, Morrison M. Differences down-under: alcohol-fueled methanogenesis by archaea present in Australian macropodids. ISME J 2016;10:2376-88. [PMID: 27022996 DOI: 10.1038/ismej.2016.41] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]
471 Jiao N, Baker SS, Nugent CA, Tsompana M, Cai L, Wang Y, Buck MJ, Genco RJ, Baker RD, Zhu R, Zhu L. Gut microbiome may contribute to insulin resistance and systemic inflammation in obese rodents: A meta-analysis. Physiol Genomics. 2018;50:244-254. [PMID: 29373083 DOI: 10.1152/physiolgenomics.00114.2017] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 25.0] [Reference Citation Analysis]
472 Labonte AC, Tosello-Trampont AC, Hahn YS. The role of macrophage polarization in infectious and inflammatory diseases. Mol Cells 2014;37:275-85. [PMID: 24625576 DOI: 10.14348/molcells.2014.2374] [Cited by in Crossref: 199] [Cited by in F6Publishing: 182] [Article Influence: 28.4] [Reference Citation Analysis]
473 Loomba R, Ling L, Dinh DM, DePaoli AM, Lieu HD, Harrison SA, Sanyal AJ. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH. Hepatology 2021;73:126-43. [PMID: 32794259 DOI: 10.1002/hep.31523] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
474 Wu L, Li J, Feng J, Ji J, Yu Q, Li Y, Zheng Y, Dai W, Wu J, Guo C. Crosstalk between PPARs and gut microbiota in NAFLD. Biomed Pharmacother 2021;136:111255. [PMID: 33485064 DOI: 10.1016/j.biopha.2021.111255] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
475 Haraguchi M, Miuma S, Masumoto H, Ichikawa T, Kanda Y, Sasaki R, Fukushima M, Miyaaki H, Taura N, Nakao K. Bacteroides in colonic mucosa-associated microbiota affects the development of minimal hepatic encephalopathy in patients with cirrhosis. Hepatol Int 2019;13:482-9. [DOI: 10.1007/s12072-019-09963-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
476 Maher JJ. Pathogenesis of NAFLD and NASH. In: Chalasani N, Szabo G, editors. Alcoholic and Non-Alcoholic Fatty Liver Disease. Cham: Springer International Publishing; 2016. pp. 71-101. [DOI: 10.1007/978-3-319-20538-0_4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
477 Everard A, Matamoros S, Geurts L, Delzenne NM, Cani PD. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. mBio 2014;5:e01011-14. [PMID: 24917595 DOI: 10.1128/mBio.01011-14] [Cited by in Crossref: 119] [Cited by in F6Publishing: 63] [Article Influence: 17.0] [Reference Citation Analysis]
478 Pierri L, Saggese P, Guercio Nuzio S, Troisi J, Di Stasi M, Poeta M, Savastano R, Marchese G, Tarallo R, Massa G, Ciccone V, Ziegenhardt D, Cavallo P, Bergheim I, Weisz A, Vajro P. Relations of gut liver axis components and gut microbiota in obese children with fatty liver: A pilot study. Clin Res Hepatol Gastroenterol 2018;42:387-90. [PMID: 29773420 DOI: 10.1016/j.clinre.2018.03.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
479 Hu X, Wang T, Liang S, Li W, Wu X, Jin F. Antibiotic-induced imbalances in gut microbiota aggravates cholesterol accumulation and liver injuries in rats fed a high-cholesterol diet. Appl Microbiol Biotechnol 2015;99:9111-22. [PMID: 26129950 DOI: 10.1007/s00253-015-6753-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
480 Xie X, Zhang L, Yuan S, Li H, Zheng C, Xie S, Sun Y, Zhang C, Wang R, Jin Y. Val-Val-Tyr-Pro protects against non-alcoholic steatohepatitis in mice by modulating the gut microbiota and gut-liver axis activation. J Cell Mol Med 2021;25:1439-55. [PMID: 33400402 DOI: 10.1111/jcmm.16229] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
481 Foster MT, Gentile CL, Cox-york K, Wei Y, Wang D, Estrada AL, Reese L, Miller T, Pagliassotti MJ, Weir TL. Fuzhuan tea consumption imparts hepatoprotective effects and alters intestinal microbiota in high saturated fat diet-fed rats. Mol Nutr Food Res 2016;60:1213-20. [DOI: 10.1002/mnfr.201500654] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 7.4] [Reference Citation Analysis]
482 Puri P, Liangpunsakul S, Christensen JE, Shah VH, Kamath PS, Gores GJ, Walker S, Comerford M, Katz B, Borst A, Yu Q, Kumar DP, Mirshahi F, Radaeva S, Chalasani NP, Crabb DW, Sanyal AJ; TREAT Consortium. The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. Hepatology 2018;67:1284-302. [PMID: 29083504 DOI: 10.1002/hep.29623] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 19.3] [Reference Citation Analysis]
483 Burcelin R, Serino M, Chabo C, Garidou L, Pomié C, Courtney M, Amar J, Bouloumié A. Metagenome and metabolism: the tissue microbiota hypothesis: Burcelin et al. Diabetes Obes Metab 2013;15:61-70. [DOI: 10.1111/dom.12157] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 9.8] [Reference Citation Analysis]
484 Huang Z, Chen M, Guo W, Li T, Liu B, Bai W, Ai L, Rao P, Ni L, Lv X. Monascus purpureus-fermented common buckwheat protects against dyslipidemia and non-alcoholic fatty liver disease through the regulation of liver metabolome and intestinal microbiome. Food Research International 2020;136:109511. [DOI: 10.1016/j.foodres.2020.109511] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
485 Li CL, Zhou WJ, Ji G, Zhang L. Natural products that target macrophages in treating non-alcoholic steatohepatitis. World J Gastroenterol 2020;26:2155-65. [PMID: 32476782 DOI: 10.3748/wjg.v26.i18.2155] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
486 Yang M, Zhang CY. G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment. World J Gastroenterol 2021;27:677-91. [PMID: 33716447 DOI: 10.3748/wjg.v27.i8.677] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
487 Zhu L, Baker RD, Zhu R, Baker SS. Sequencing the gut metagenome as a noninvasive diagnosis for advanced nonalcoholic steatohepatitis. Hepatology. 2017;66:2080-2083. [PMID: 28732121 DOI: 10.1002/hep.29387] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
488 Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung H, Yun KE, Shin H, Ryu S. Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study: Hepatology. Hepatology 2019;69:64-75. [DOI: 10.1002/hep.30170] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 16.0] [Reference Citation Analysis]
489 Porras D, Nistal E, Martínez-Flórez S, Olcoz JL, Jover R, Jorquera F, González-Gallego J, García-Mediavilla MV, Sánchez-Campos S. Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice. Mol Nutr Food Res 2019;63:e1800930. [PMID: 30680920 DOI: 10.1002/mnfr.201800930] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 14.0] [Reference Citation Analysis]
490 Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:7381-7391. [PMID: 24966608 DOI: 10.3748/wjg.v20.i23.7381] [Cited by in CrossRef: 178] [Cited by in F6Publishing: 141] [Article Influence: 29.7] [Reference Citation Analysis]
491 Ye JZ, Li YT, Wu WR, Shi D, Fang DQ, Yang LY, Bian XY, Wu JJ, Wang Q, Jiang XW, Peng CG, Ye WC, Xia PC, Li LJ. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis. World J Gastroenterol 2018;24:2468-81. [PMID: 29930468 DOI: 10.3748/wjg.v24.i23.2468] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
492 Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2013;56:461-468. [PMID: 23287807 DOI: 10.1016/j.numecd.2012.02.007] [Cited by in Crossref: 229] [Cited by in F6Publishing: 213] [Article Influence: 28.6] [Reference Citation Analysis]
493 Tardelli M, Bruschi FV, Fuchs CD, Claudel T, Auer N, Kunczer V, Baumgartner M, A H O Ronda O, Verkade HJ, Stojakovic T, Scharnagl H, Habib A, Zimmermann R, Lotersztajn S, Trauner M. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis. Hepatology. 2020;71:1750-1765. [PMID: 31505038 DOI: 10.1002/hep.30929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
494 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15:397-411. [PMID: 29748586 DOI: 10.1038/s41575-018-0011-z] [Cited by in Crossref: 301] [Cited by in F6Publishing: 250] [Article Influence: 150.5] [Reference Citation Analysis]
495 Moreira GV, Azevedo FF, Ribeiro LM, Santos A, Guadagnini D, Gama P, Liberti EA, Saad M, Carvalho C. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice. J Nutr Biochem 2018;62:143-54. [PMID: 30292107 DOI: 10.1016/j.jnutbio.2018.07.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 14.7] [Reference Citation Analysis]
496 Kim AH, Lee Y, Kim E, Ji SC, Chung JY, Cho JY. Assessment of Oral Vancomycin-Induced Alterations in Gut Bacterial Microbiota and Metabolome of Healthy Men. Front Cell Infect Microbiol 2021;11:629438. [PMID: 34123865 DOI: 10.3389/fcimb.2021.629438] [Reference Citation Analysis]
497 Jung Y, Kim I, Mannaa M, Kim J, Wang S, Park I, Kim J, Seo YS. Effect of Kombucha on gut-microbiota in mouse having non-alcoholic fatty liver disease. Food Sci Biotechnol 2019;28:261-7. [PMID: 30815318 DOI: 10.1007/s10068-018-0433-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
498 Schwabe RF, Greten TF. Gut microbiome in HCC - Mechanisms, diagnosis and therapy. J Hepatol. 2020;72:230-238. [PMID: 31954488 DOI: 10.1016/j.jhep.2019.08.016] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 51.0] [Reference Citation Analysis]
499 Mancini A, Campagna F, Amodio P, Tuohy KM. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy. Food Funct. 2018;9:1373-1388. [PMID: 29485654 DOI: 10.1039/c7fo01528c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 8.3] [Reference Citation Analysis]
500 Zeng Y, Chen S, Fu Y, Wu W, Chen T, Chen J, Yang B, Ou Q. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. J Viral Hepat 2020;27:143-55. [PMID: 31600845 DOI: 10.1111/jvh.13216] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
501 Tranah TH, Edwards LA, Schnabl B, Shawcross DL. Targeting the gut-liver-immune axis to treat cirrhosis. Gut 2021;70:982-94. [PMID: 33060124 DOI: 10.1136/gutjnl-2020-320786] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
502 López-Moreno A, Acuña I, Torres-Sánchez A, Ruiz-Moreno Á, Cerk K, Rivas A, Suárez A, Monteoliva-Sánchez M, Aguilera M. Next Generation Probiotics for Neutralizing Obesogenic Effects: Taxa Culturing Searching Strategies. Nutrients 2021;13:1617. [PMID: 34065873 DOI: 10.3390/nu13051617] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
503 Lin YC, Lu HF, Chen JC, Huang HC, Chen YH, Su YS, Tung CY, Huang C. Purple-leaf tea (Camellia sinensis L.) ameliorates high-fat diet induced obesity and metabolic disorder through the modulation of the gut microbiota in mice. BMC Complement Med Ther 2020;20:376. [PMID: 33302947 DOI: 10.1186/s12906-020-03171-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
504 Tameez Ud Din A, Alam F, Tameez-Ud-Din A, Chaudhary FMD. Auto-Brewery Syndrome: A Clinical Dilemma. Cureus 2020;12:e10983. [PMID: 33209539 DOI: 10.7759/cureus.10983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
505 Magee N, Zou A, Zhang Y. Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells. Biomed Res Int. 2016;2016:5170402. [PMID: 27822476 DOI: 10.1155/2016/5170402] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 10.8] [Reference Citation Analysis]
506 Jiang H, Li J, Zhang B, Huang R, Zhang J, Chen Z, Shang X, Li X, Nie X. Intestinal Flora Disruption and Novel Biomarkers Associated With Nasopharyngeal Carcinoma. Front Oncol 2019;9:1346. [PMID: 31867274 DOI: 10.3389/fonc.2019.01346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
507 Duvallet C, Gibbons SM, Gurry T, Irizarry RA, Alm EJ. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. Nat Commun 2017;8:1784. [PMID: 29209090 DOI: 10.1038/s41467-017-01973-8] [Cited by in Crossref: 347] [Cited by in F6Publishing: 264] [Article Influence: 86.8] [Reference Citation Analysis]
508 Aitbaev KA, Murkamilov IT, Fomin VV. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation]. Ter Arkh 2017;89:120-8. [PMID: 28914862 DOI: 10.17116/terarkh2017898120-128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
509 Oduaran OH, Tamburini FB, Sahibdeen V, Brewster R, Gómez-Olivé FX, Kahn K, Norris SA, Tollman SM, Twine R, Wade AN, Wagner RG, Lombard Z, Bhatt AS, Hazelhurst S. Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition. BMC Microbiol 2020;20:330. [PMID: 33129264 DOI: 10.1186/s12866-020-02017-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
510 Minemura M, Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol 2015;21:1691-702. [PMID: 25684933 DOI: 10.3748/wjg.v21.i6.1691] [Cited by in CrossRef: 80] [Cited by in F6Publishing: 68] [Article Influence: 13.3] [Reference Citation Analysis]
511 Lamas B, Martins Breyner N, Houdeau E. Impacts of foodborne inorganic nanoparticles on the gut microbiota-immune axis: potential consequences for host health. Part Fibre Toxicol 2020;17:19. [PMID: 32487227 DOI: 10.1186/s12989-020-00349-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 31.0] [Reference Citation Analysis]
512 Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. Publisher Correction: The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018;15:785. [PMID: 29785003 DOI: 10.1038/s41575-018-0031-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 6.7] [Reference Citation Analysis]
513 Matsushita N, Osaka T, Haruta I, Ueshiba H, Yanagisawa N, Omori-Miyake M, Hashimoto E, Shibata N, Tokushige K, Saito K. Effect of Lipopolysaccharide on the Progression of Non-Alcoholic Fatty Liver Disease in High Caloric Diet-Fed Mice. Scand J Immunol. 2016;83:109-118. [PMID: 26524607 DOI: 10.1111/sji.12397] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
514 Wu J, Wang K, Wang X, Pang Y, Jiang C. The role of the gut microbiome and its metabolites in metabolic diseases. Protein Cell 2021;12:360-73. [PMID: 33346905 DOI: 10.1007/s13238-020-00814-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
515 Gómez-Zorita S, Aguirre L, Milton-Laskibar I, Fernández-Quintela A, Trepiana J, Kajarabille N, Mosqueda-Solís A, González M, Portillo MP. Relationship between Changes in Microbiota and Liver Steatosis Induced by High-Fat Feeding-A Review of Rodent Models. Nutrients 2019;11:E2156. [PMID: 31505802 DOI: 10.3390/nu11092156] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
516 Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, Iio E, Nojiri S, Fujiwara K, Yoneda M, Yoshiji H, Tanaka Y. Gut Dysbiosis Associated With Hepatitis C Virus Infection.Clin Infect Dis. 2018;67:869-877. [PMID: 29718124 DOI: 10.1093/cid/ciy205] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 35.0] [Reference Citation Analysis]
517 Acharya C, Bajaj JS. Gut Microbiota and Complications of Liver Disease. Gastroenterol Clin North Am. 2017;46:155-169. [PMID: 28164848 DOI: 10.1016/j.gtc.2016.09.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 13.0] [Reference Citation Analysis]
518 Du X, Zhang J, Zhang X, Schramm KW, Nan B, Huang Q, Tian M, Shen H. Persistence and reversibility of arsenic-induced gut microbiome and metabolome shifts in male rats after 30-days recovery duration. Sci Total Environ 2021;776:145972. [PMID: 33647652 DOI: 10.1016/j.scitotenv.2021.145972] [Reference Citation Analysis]
519 Duseja A, Chawla YK. Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis. 2014;18:59-71. [PMID: 24274865 DOI: 10.1016/j.cld.2013.09.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 7.8] [Reference Citation Analysis]
520 Qi L, Dai W, Kong J, Tian Y, Chen Y. Cholecystectomy as a risk factor for metabolic dysfunction-associated fatty liver disease: unveiling the metabolic and chronobiologic clues behind the bile acid enterohepatic circulation. J Physiol Biochem 2021. [PMID: 34302623 DOI: 10.1007/s13105-020-00782-w] [Reference Citation Analysis]
521 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Reference Citation Analysis]
522 Duwaerts CC, Maher JJ. Mechanisms of Liver Injury in Non-Alcoholic Steatohepatitis. Curr Hepatol Rep 2014;13:119-29. [PMID: 25045618 DOI: 10.1007/s11901-014-0224-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
523 Vacca M, Celano G, Calabrese FM, Portincasa P, Gobbetti M, De Angelis M. The Controversial Role of Human Gut Lachnospiraceae. Microorganisms 2020;8:E573. [PMID: 32326636 DOI: 10.3390/microorganisms8040573] [Cited by in Crossref: 104] [Cited by in F6Publishing: 80] [Article Influence: 104.0] [Reference Citation Analysis]
524 Nakamoto N, Amiya T, Aoki R, Taniki N, Koda Y, Miyamoto K, Teratani T, Suzuki T, Chiba S, Chu PS, Hayashi A, Yamaguchi A, Shiba S, Miyake R, Katayama T, Suda W, Mikami Y, Kamada N, Ebinuma H, Saito H, Hattori M, Kanai T. Commensal Lactobacillus Controls Immune Tolerance during Acute Liver Injury in Mice. Cell Rep 2017;21:1215-26. [PMID: 29091761 DOI: 10.1016/j.celrep.2017.10.022] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 13.7] [Reference Citation Analysis]
525 Greuter T, Malhi H, Gores GJ, Shah VH. Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight 2017;2:95354. [PMID: 28878132 DOI: 10.1172/jci.insight.95354] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
526 Patel S, Behara R, Swanson GR, Forsyth CB, Voigt RM, Keshavarzian A. Alcohol and the Intestine. Biomolecules 2015;5:2573-88. [PMID: 26501334 DOI: 10.3390/biom5042573] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 5.7] [Reference Citation Analysis]
527 Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res 2019;3:3-18. [PMID: 32461811 DOI: 10.1016/j.livres.2019.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
528 Quagliariello A, Del Chierico F, Russo A, Reddel S, Conte G, Lopetuso LR, Ianiro G, Dallapiccola B, Cardona F, Gasbarrini A, Putignani L. Gut Microbiota Profiling and Gut-Brain Crosstalk in Children Affected by Pediatric Acute-Onset Neuropsychiatric Syndrome and Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. Front Microbiol 2018;9:675. [PMID: 29686658 DOI: 10.3389/fmicb.2018.00675] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 12.3] [Reference Citation Analysis]
529 Ho A, Sinick J, Esko T, Fischer K, Menni C, Zierer J, Matey-Hernandez M, Fortney K, Morgen EK. Circulating glucuronic acid predicts healthspan and longevity in humans and mice. Aging (Albany NY) 2019;11:7694-706. [PMID: 31557729 DOI: 10.18632/aging.102281] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
530 Fukuda S, Ohno H. Gut microbiome and metabolic diseases. Semin Immunopathol. 2014;36:103-114. [PMID: 24196453 DOI: 10.1007/s00281-013-0399-z] [Cited by in Crossref: 87] [Cited by in F6Publishing: 70] [Article Influence: 10.9] [Reference Citation Analysis]
531 Shapiro H, Suez J, Elinav E. Personalized microbiome-based approaches to metabolic syndrome management and prevention. J Diabetes 2017;9:226-36. [PMID: 27787945 DOI: 10.1111/1753-0407.12501] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
532 Briskey D, Heritage M, Jaskowski LA, Peake J, Gobe G, Subramaniam VN, Crawford D, Campbell C, Vitetta L. Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2016;9:463-72. [PMID: 27366215 DOI: 10.1177/1756283X16645055] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
533 Zhang S, Wong YT, Tang KY, Kwan HY, Su T. Chinese Medicinal Herbs Targeting the Gut-Liver Axis and Adipose Tissue-Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science. Front Endocrinol (Lausanne) 2020;11:572729. [PMID: 33101207 DOI: 10.3389/fendo.2020.572729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
534 Wang PX, Deng XR, Zhang CH, Yuan HJ. Gut microbiota and metabolic syndrome. Chin Med J (Engl). 2020;133:808-816. [PMID: 32106124 DOI: 10.1097/cm9.0000000000000696] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
535 Ichikawa H, Imoto H, Tanaka N, Fujishima F, Tsuchiya T, Watanabe K, Aoki T, Kohyama A, Morikawa T, Ohnuma S, Naitoh T, Kamei T, Unno M. The role of bilio-pancreatic limb in nonalcoholic steatohepatitis improvement after duodenal-jejunal bypass in rats. Surgery 2021:S0039-6060(21)00679-6. [PMID: 34389163 DOI: 10.1016/j.surg.2021.07.003] [Reference Citation Analysis]
536 Wu LL, Huang TS, Shyu YC, Wang CL, Wang HY, Chen PJ. Gut microbiota in the innate immunity against hepatitis B virus - implication in age-dependent HBV clearance. Curr Opin Virol 2021;49:194-202. [PMID: 34242953 DOI: 10.1016/j.coviro.2021.06.006] [Reference Citation Analysis]
537 Wang C, Zhu C, Shao L, Ye J, Shen Y, Ren Y. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. Mediators Inflamm. 2019;2019:7659509. [PMID: 31341422 DOI: 10.1155/2019/7659509] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
538 Dongiovanni P, Valenti L. A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2017;18:E1534. [PMID: 28714900 DOI: 10.3390/ijms18071534] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
539 Garcia-Beltran C, Malpique R, Carbonetto B, González-Torres P, Henares D, Brotons P, Muñoz-Almagro C, López-Bermejo A, de Zegher F, Ibáñez L. Gut microbiota in adolescent girls with polycystic ovary syndrome: Effects of randomized treatments. Pediatr Obes 2021;16:e12734. [PMID: 32989872 DOI: 10.1111/ijpo.12734] [Reference Citation Analysis]
540 Joice R, Yasuda K, Shafquat A, Morgan XC, Huttenhower C. Determining microbial products and identifying molecular targets in the human microbiome. Cell Metab 2014;20:731-41. [PMID: 25440055 DOI: 10.1016/j.cmet.2014.10.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 47] [Article Influence: 9.4] [Reference Citation Analysis]
541 Ponziani FR, Pecere S, Gasbarrini A, Ojetti V. Physiology and pathophysiology of liver lipid metabolism. Expert Review of Gastroenterology & Hepatology 2015;9:1055-67. [DOI: 10.1586/17474124.2015.1056156] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
542 Bayoumy AB, Mulder CJJ, Mol JJ, Tushuizen ME. Gut fermentation syndrome: A systematic review of case reports. United European Gastroenterol J 2021;9:332-42. [PMID: 33887125 DOI: 10.1002/ueg2.12062] [Reference Citation Analysis]
543 Jasirwan COM, Lesmana CRA, Hasan I, Sulaiman AS, Gani RA. The role of gut microbiota in non-alcoholic fatty liver disease: pathways of mechanisms. Biosci Microbiota Food Health 2019;38:81-8. [PMID: 31384519 DOI: 10.12938/bmfh.18-032] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
544 Thomas CE, Luu HN, Wang R, Adams-Haduch J, Jin A, Koh WP, Yuan JM. Association between Dietary Tomato Intake and the Risk of Hepatocellular Carcinoma: The Singapore Chinese Health Study. Cancer Epidemiol Biomarkers Prev 2020;29:1430-5. [PMID: 32284341 DOI: 10.1158/1055-9965.EPI-20-0051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
545 Colak Y, Hasan B, Erkalma B, Tandon K, Zervos X, Menzo EL, Erim T. Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target. Clin Res Hepatol Gastroenterol 2021;45:101710. [PMID: 33930586 DOI: 10.1016/j.clinre.2021.101710] [Reference Citation Analysis]
546 Dai Z, Wu Z, Hang S, Zhu W, Wu G. Amino acid metabolism in intestinal bacteria and its potential implications for mammalian reproduction. Mol Hum Reprod 2015;21:389-409. [PMID: 25609213 DOI: 10.1093/molehr/gav003] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 12.7] [Reference Citation Analysis]
547 Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65:425-443. [PMID: 27091791 DOI: 10.1016/j.jhep.2016.04.005] [Cited by in Crossref: 190] [Cited by in F6Publishing: 161] [Article Influence: 38.0] [Reference Citation Analysis]
548 Ishioka M, Miura K, Minami S, Shimura Y, Ohnishi H. Altered Gut Microbiota Composition and Immune Response in Experimental Steatohepatitis Mouse Models. Dig Dis Sci. 2017;62:396-406. [PMID: 27913996 DOI: 10.1007/s10620-016-4393-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
549 Zhou D, Fan JG. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25:2019-2028. [PMID: 31114130 DOI: 10.3748/wjg.v25.i17.2019] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
550 Brockman DA, Chen X, Gallaher DD. High-viscosity dietary fibers reduce adiposity and decrease hepatic steatosis in rats fed a high-fat diet. J Nutr 2014;144:1415-22. [PMID: 24991042 DOI: 10.3945/jn.114.191577] [Cited by in Crossref: 43] [Cited by in F6Publishing: 28] [Article Influence: 6.1] [Reference Citation Analysis]
551 Hoozemans J, de Brauw M, Nieuwdorp M, Gerdes V. Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review. Metabolites 2021;11:353. [PMID: 34072995 DOI: 10.3390/metabo11060353] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
552 Chen EB, Cason C, Gilbert JA, Ho KJ. Current State of Knowledge on Implications of Gut Microbiome for Surgical Conditions. J Gastrointest Surg 2018;22:1112-23. [PMID: 29623674 DOI: 10.1007/s11605-018-3755-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
553 Dong TS, Jacobs JP. Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver? Exp Biol Med (Maywood) 2019;244:408-18. [PMID: 30871368 DOI: 10.1177/1535370219836739] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
554 Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med 2020;9:E2648. [PMID: 32823983 DOI: 10.3390/jcm9082648] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
555 Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015;21:11053-76. [PMID: 26494962 DOI: 10.3748/wjg.v21.i39.11053] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 26] [Article Influence: 7.4] [Reference Citation Analysis]
556 Koh JC, Loo WM, Goh KL, Sugano K, Chan WK, Chiu WY, Choi MG, Gonlachanvit S, Lee WJ, Lee WJ. Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. J Gastroenterol Hepatol. 2016;31:1405-1413. [PMID: 27010240 DOI: 10.1111/jgh.13385] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
557 Mayneris-Perxachs J, Cardellini M, Hoyles L, Latorre J, Davato F, Moreno-Navarrete JM, Arnoriaga-Rodríguez M, Serino M, Abbott J, Barton RH, Puig J, Fernández-Real X, Ricart W, Tomlinson C, Woodbridge M, Gentileschi P, Butcher SA, Holmes E, Nicholson JK, Pérez-Brocal V, Moya A, Clain DM, Burcelin R, Dumas ME, Federici M, Fernández-Real JM. Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome. Microbiome 2021;9:104. [PMID: 33962692 DOI: 10.1186/s40168-021-01052-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
558 Shen TD, Pyrsopoulos N, Rustgi VK. Microbiota and the liver: Microbiota and the Liver. Liver Transpl 2018;24:539-50. [DOI: 10.1002/lt.25008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
559 Vilar-Gomez E, Sookoian S, Pirola CJ, Liang T, Gawrieh S, Cummings O, Liu W, Chalasani NP. ADH1B∗2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption. Gastroenterology 2020;159:929-43. [PMID: 32454036 DOI: 10.1053/j.gastro.2020.05.054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
560 Lambert JE, Parnell JA, Eksteen B, Raman M, Bomhof MR, Rioux KP, Madsen KL, Reimer RA. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterol 2015;15:169. [PMID: 26635079 DOI: 10.1186/s12876-015-0400-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
561 Özkul C, Yalınay M, Karakan T. Islamic fasting leads to an increased abundance of Akkermansia muciniphila and Bacteroides fragilis group: A preliminary study on intermittent fasting. Turk J Gastroenterol 2019;30:1030-5. [PMID: 31854308 DOI: 10.5152/tjg.2019.19185] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
562 Jiang JW, Ren ZG, Lu HF, Zhang H, Li A, Cui GY, Jia JJ, Xie HY, Chen XH, He Y, Jiang L, Li LJ. Optimal immunosuppressor induces stable gut microbiota after liver transplantation. World J Gastroenterol 2018;24:3871-83. [PMID: 30228781 DOI: 10.3748/wjg.v24.i34.3871] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
563 Zhai S, Zhu L, Qin S, Li L. Effect of lactulose intervention on gut microbiota and short chain fatty acid composition of C57BL/6J mice. Microbiologyopen 2018;7:e00612. [PMID: 29575825 DOI: 10.1002/mbo3.612] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
564 Giuffrè M, Campigotto M, Campisciano G, Comar M, Crocè LS. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature. Am J Physiol Gastrointest Liver Physiol 2020;318:G889-906. [PMID: 32146836 DOI: 10.1152/ajpgi.00161.2019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 27.0] [Reference Citation Analysis]
565 Zhang H, Liu M, Zhong W, Zheng Y, Li Y, Guo L, Zhang Y, Ran Y, Zhao J, Zhou L, Wang B. Leaky Gut Driven by Dysbiosis Augments Activation and Accumulation of Liver Macrophages via RIP3 Signaling Pathway in Autoimmune Hepatitis. Front Immunol 2021;12:624360. [PMID: 33841405 DOI: 10.3389/fimmu.2021.624360] [Reference Citation Analysis]
566 Hartmann P, Schnabl B. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2021;41:87-102. [PMID: 33957682 DOI: 10.1055/s-0040-1719174] [Reference Citation Analysis]
567 Solga SF. Breath volatile organic compounds for the gut-fatty liver axis: promise, peril, and path forward. World J Gastroenterol 2014;20:9017-25. [PMID: 25083075 DOI: 10.3748/wjg.v20.i27.9017] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
568 Marek E, Kraft WK. Ethanol pharmacokinetics in neonates and infants. Curr Ther Res Clin Exp 2014;76:90-7. [PMID: 25379066 DOI: 10.1016/j.curtheres.2014.09.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 5.1] [Reference Citation Analysis]
569 Pataky Z, Genton L, Spahr L, Lazarevic V, Terraz S, Gaïa N, Rubbia-brandt L, Golay A, Schrenzel J, Pichard C. Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study. Dig Dis Sci 2016;61:2721-31. [DOI: 10.1007/s10620-016-4179-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 7.2] [Reference Citation Analysis]
570 Hiippala K, Jouhten H, Ronkainen A, Hartikainen A, Kainulainen V, Jalanka J, Satokari R. The Potential of Gut Commensals in Reinforcing Intestinal Barrier Function and Alleviating Inflammation. Nutrients 2018;10:E988. [PMID: 30060606 DOI: 10.3390/nu10080988] [Cited by in Crossref: 143] [Cited by in F6Publishing: 118] [Article Influence: 47.7] [Reference Citation Analysis]
571 Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 2019;76:1541-58. [PMID: 30683985 DOI: 10.1007/s00018-019-03011-w] [Cited by in Crossref: 101] [Cited by in F6Publishing: 76] [Article Influence: 50.5] [Reference Citation Analysis]
572 Lee S, Knotts TA, Goodson ML, Barboza M, Wudeck E, England G, Raybould HE. Metabolic Responses to Butyrate Supplementation in LF- and HF-Fed Mice Are Cohort-Dependent and Associated with Changes in Composition and Function of the Gut Microbiota. Nutrients 2020;12:E3524. [PMID: 33207675 DOI: 10.3390/nu12113524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
573 Cho MS, Kim SY, Suk KT, Kim BY. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol. 2018;56:855-867. [PMID: 30377993 DOI: 10.1007/s12275-018-8346-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
574 Yang L, Lin W, Nugent CA, Hao S, Song H, Liu T, Zheng P. Lingguizhugan Decoction Protects against High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease by Alleviating Oxidative Stress and Activating Cholesterol Secretion. International Journal of Genomics 2017;2017:1-12. [DOI: 10.1155/2017/2790864] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
575 Panera N, Barbaro B, Della Corte C, Mosca A, Nobili V, Alisi A. A review of the pathogenic and therapeutic role of nutrition in pediatric nonalcoholic fatty liver disease. Nutrition Research 2018;58:1-16. [DOI: 10.1016/j.nutres.2018.05.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
576 Duarte SMB, Stefano JT, Miele L, Ponziani FR, Souza-Basqueira M, Okada LSRR, de Barros Costa FG, Toda K, Mazo DFC, Sabino EC, Carrilho FJ, Gasbarrini A, Oliveira CP. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: A prospective pilot study. Nutr Metab Cardiovasc Dis. 2018;28:369-384. [PMID: 29482963 DOI: 10.1016/j.numecd.2017.10.014] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 11.3] [Reference Citation Analysis]
577 Caussy C, Hsu C, Singh S, Bassirian S, Kolar J, Faulkner C, Sinha N, Bettencourt R, Gara N, Valasek MA, Schnabl B, Richards L, Brenner DA, Hofmann AF, Loomba R. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD. Aliment Pharmacol Ther 2019;49:183-93. [PMID: 30506692 DOI: 10.1111/apt.15035] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
578 Garcia-Simon M, Morales JM, Modesto-Alapont V, Gonzalez-Marrachelli V, Vento-Rehues R, Jorda-Miñana A, Blanquer-Olivas J, Monleon D. Prognosis Biomarkers of Severe Sepsis and Septic Shock by 1H NMR Urine Metabolomics in the Intensive Care Unit. PLoS One 2015;10:e0140993. [PMID: 26565633 DOI: 10.1371/journal.pone.0140993] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
579 Delaune V, Orci LA, Lacotte S, Peloso A, Schrenzel J, Lazarevic V, Toso C. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response. Expert Opin Biol Ther 2018;18:1061-71. [PMID: 30173562 DOI: 10.1080/14712598.2018.1518424] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
580 Fernandez-Cantos MV, Garcia-Morena D, Iannone V, El-Nezami H, Kolehmainen M, Kuipers OP. Role of microbiota and related metabolites in gastrointestinal tract barrier function in NAFLD. Tissue Barriers 2021;:1879719. [PMID: 34280073 DOI: 10.1080/21688370.2021.1879719] [Reference Citation Analysis]
581 Gao Y, Yang L, Chin Y, Liu F, Li RW, Yuan S, Xue C, Xu J, Tang Q. Astaxanthin n-Octanoic Acid Diester Ameliorates Insulin Resistance and Modulates Gut Microbiota in High-Fat and High-Sucrose Diet-Fed Mice. Int J Mol Sci 2020;21:E2149. [PMID: 32245087 DOI: 10.3390/ijms21062149] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
582 Zhang Y, Li J, Zhang Y, Wang Y. Intestinal microbiota participates in nonalcoholic fatty liver disease progression by affecting intestinal homeostasis. WJCC 2021;9:6654-62. [DOI: 10.12998/wjcc.v9.i23.6654] [Reference Citation Analysis]
583 Li R, Mao Z, Ye X, Zuo T. Human Gut Microbiome and Liver Diseases: From Correlation to Causation. Microorganisms 2021;9:1017. [PMID: 34066850 DOI: 10.3390/microorganisms9051017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
584 Wirbel J, Zych K, Essex M, Karcher N, Kartal E, Salazar G, Bork P, Sunagawa S, Zeller G. Microbiome meta-analysis and cross-disease comparison enabled by the SIAMCAT machine learning toolbox. Genome Biol 2021;22:93. [PMID: 33785070 DOI: 10.1186/s13059-021-02306-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
585 Acharya C, Bajaj JS. Chronic Liver Diseases and the Microbiome-Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. Gastroenterology 2021;160:556-72. [PMID: 33253686 DOI: 10.1053/j.gastro.2020.10.056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
586 Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Moyses HE, Clough GF, Wright M, Patel J, Bindels L, Delzenne NM, Calder PC, Byrne CD. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease. Contemp Clin Trials 2018;71:113-23. [PMID: 29787859 DOI: 10.1016/j.cct.2018.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
587 Tan Y, Wei Z, Chen J, An J, Li M, Zhou L, Men Y, Zhao S. Save your gut save your age: The role of the microbiome in stem cell ageing. J Cell Mol Med 2019;23:4866-75. [PMID: 31207055 DOI: 10.1111/jcmm.14373] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
588 Ebrahimzadeh Leylabadlo H, Ghotaslou R, Samadi Kafil H, Feizabadi MM, Moaddab SY, Farajnia S, Sheykhsaran E, Sanaie S, Shanehbandi D, Bannazadeh Baghi H. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. Eur J Clin Microbiol Infect Dis 2020;39:613-27. [PMID: 31828683 DOI: 10.1007/s10096-019-03746-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
589 Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol 2021;18:73-91. [PMID: 33268887 DOI: 10.1038/s41423-020-00579-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
590 Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60:940-947. [PMID: 24374295 DOI: 10.1016/j.jhep.2013.12.019] [Cited by in Crossref: 495] [Cited by in F6Publishing: 410] [Article Influence: 61.9] [Reference Citation Analysis]
591 Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol 2013;29:264-70. [PMID: 23493073 DOI: 10.1097/MOG.0b013e32835ff948] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
592 Sharma M, Arora I, Stoll ML, Li Y, Morrow CD, Barnes S, Berryhill TF, Li S, Tollefsbol TO. Nutritional combinatorial impact on the gut microbiota and plasma short-chain fatty acids levels in the prevention of mammary cancer in Her2/neu estrogen receptor-negative transgenic mice. PLoS One 2020;15:e0234893. [PMID: 33382695 DOI: 10.1371/journal.pone.0234893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
593 Sun J. Dietary vitamin D, vitamin D receptor, and microbiome. Curr Opin Clin Nutr Metab Care 2018;21:471-4. [PMID: 30169457 DOI: 10.1097/MCO.0000000000000516] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
594 Watahiki T, Okada K, Warabi E, Nagaoka T, Suzuki H, Ishige K, Yanagawa T, Takahashi S, Mizokami Y, Tokushige K, Ariizumi SI, Yamamoto M, Shoda J. Gender difference in development of steatohepatitis in p62/Sqstm1 and Nrf2 double-knockout mice. Exp Anim 2020;69:395-406. [PMID: 32493884 DOI: 10.1538/expanim.20-0028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
595 Thiele I, Sahoo S, Heinken A, Hertel J, Heirendt L, Aurich MK, Fleming RM. Personalized whole-body models integrate metabolism, physiology, and the gut microbiome. Mol Syst Biol 2020;16:e8982. [PMID: 32463598 DOI: 10.15252/msb.20198982] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 32.0] [Reference Citation Analysis]
596 Liu W, Baker RD, Bhatia T, Zhu L, Baker SS. Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci. 2016;73:1969-1987. [PMID: 26894897 DOI: 10.1007/s00018-016-2161-x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 18.2] [Reference Citation Analysis]
597 Rivero-Gutiérrez B, Gámez-Belmonte R, Suárez MD, Lavín JL, Aransay AM, Olivares M, Martínez-Augustin O, Sánchez de Medina F, Zarzuelo A. A synbiotic composed of Lactobacillus fermentum CECT5716 and FOS prevents the development of fatty acid liver and glycemic alterations in rats fed a high fructose diet associated with changes in the microbiota. Mol Nutr Food Res 2017;61. [PMID: 28463404 DOI: 10.1002/mnfr.201600622] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
598 Soufi N, Hall AM, Chen Z, Yoshino J, Collier SL, Mathews JC, Brunt EM, Albert CJ, Graham MJ, Ford DA, Finck BN. Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice. J Biol Chem 2014;289:30177-88. [PMID: 25213859 DOI: 10.1074/jbc.M114.595850] [Cited by in Crossref: 32] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
599 Desai S, Baker SS, Liu W, Moya DA, Browne RW, Mastrandrea L, Baker RD, Zhu L. Paraoxonase 1 and oxidative stress in paediatric non-alcoholic steatohepatitis. Liver Int 2014;34:110-7. [PMID: 24028323 DOI: 10.1111/liv.12308] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
600 Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2019;11: e9302. [PMID: 30591521 DOI: 10.15252/emmm.201809302] [Cited by in Crossref: 131] [Cited by in F6Publishing: 101] [Article Influence: 65.5] [Reference Citation Analysis]
601 Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases.Cell Mol Immunol. 2021;18:4-17. [PMID: 33318628 DOI: 10.1038/s41423-020-00592-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
602 Kirpich IA, Parajuli D, McClain CJ. Microbiome in NAFLD and ALD. Clin Liver Dis (Hoboken) 2015;6:55-8. [PMID: 26576267 DOI: 10.1002/cld.494] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
603 Kjærgaard K, Mikkelsen ACD, Wernberg CW, Grønkjær LL, Eriksen PL, Damholdt MF, Mookerjee RP, Vilstrup H, Lauridsen MM, Thomsen KL. Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease-Current Knowledge, Mechanisms and Perspectives. J Clin Med 2021;10:673. [PMID: 33572481 DOI: 10.3390/jcm10040673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
604 Yang J, Fernández-Galilea M, Martínez-Fernández L, González-Muniesa P, Pérez-Chávez A, Martínez JA, Moreno-Aliaga MJ. Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation. Nutrients 2019;11:E872. [PMID: 31003450 DOI: 10.3390/nu11040872] [Cited by in Crossref: 60] [Cited by in F6Publishing: 43] [Article Influence: 30.0] [Reference Citation Analysis]
605 Notarnicola M, Osella AR, Caruso MG, Pesole PL, Lippolis A, Tutino V, Bonfiglio C, De Nunzio V, Scavo MP, Mirizzi A, Franco I, Lippolis T, D'Alessandro R, Refolo MG, Messa C. Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions. Int J Mol Sci 2021;22:3899. [PMID: 33918878 DOI: 10.3390/ijms22083899] [Reference Citation Analysis]
606 Bimro ET, Hovav R, Nyska A, Glazer TA, Madar Z. High oleic peanuts improve parameters leading to fatty liver development and change the microbiota in mice intestine. Food Nutr Res 2020;64. [PMID: 33033472 DOI: 10.29219/fnr.v64.4278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
607 Oh JH, Lee JH, Cho MS, Kim H, Chun J, Lee JH, Yoon Y, Kang W. Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease. Nutrients 2021;13:1013. [PMID: 33801023 DOI: 10.3390/nu13031013] [Reference Citation Analysis]
608 Khalesi S, Johnson DW, Campbell K, Williams S, Fenning A, Saluja S, Irwin C. Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. Eur J Nutr 2018;57:2037-53. [PMID: 29119235 DOI: 10.1007/s00394-017-1568-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
609 Pallayova M, Taheri S. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies. Clin Obes. 2014;4:243-253. [PMID: 25825857 DOI: 10.1111/cob.12068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
610 Stott KJ, Phillips B, Parry L, May S. Recent advancements in the exploitation of the gut microbiome in the diagnosis and treatment of colorectal cancer. Biosci Rep 2021:BSR20204113. [PMID: 34236075 DOI: 10.1042/BSR20204113] [Reference Citation Analysis]
611 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839.2014.12.06] [Cited by in F6Publishing: 73] [Reference Citation Analysis]
612 Sookoian S, Pirola CJ. Personalizing care for nonalcoholic fatty liver disease patients: what are the research priorities? Per Med 2014;11:735-43. [PMID: 29764046 DOI: 10.2217/pme.14.44] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
613 Vittorio J, Lavine JE. Recent advances in understanding and managing pediatric nonalcoholic fatty liver disease. F1000Res 2020;9:F1000 Faculty Rev-377. [PMID: 32509277 DOI: 10.12688/f1000research.24198.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
614 Emamat H, Ghalandari H, Tangestani H, Abdollahi A, Hekmatdoost A. Artificial sweeteners are related to non-alcoholic fatty liver disease: Microbiota dysbiosis as a novel potential mechanism. EXCLI J 2020;19:620-6. [PMID: 32483408 DOI: 10.17179/excli2020-1226] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
615 Knorr J, Wree A, Tacke F, Feldstein AE. The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. Semin Liver Dis 2020;40:298-306. [PMID: 32526788 DOI: 10.1055/s-0040-1708540] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
616 Friedman JE, Dobrinskikh E, Alfonso-Garcia A, Fast A, Janssen RC, Soderborg TK, Anderson AL, Reisz JA, D'Alessandro A, Frank DN, Robertson CE, de la Houssaye BA, Johnson LK, Orlicky DJ, Wang XX, Levi M, Potma EO, El Kasmi KC, Jonscher KR. Pyrroloquinoline quinone prevents developmental programming of microbial dysbiosis and macrophage polarization to attenuate liver fibrosis in offspring of obese mice. Hepatol Commun 2018;2:313-28. [PMID: 29507905 DOI: 10.1002/hep4.1139] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
617 Boursier J, Rawls JF, Diehl AM. Obese humans with nonalcoholic fatty liver disease display alterations in fecal microbiota and volatile organic compounds. Clin Gastroenterol Hepatol. 2013;11:876-878. [PMID: 23628504 DOI: 10.1016/j.cgh.2013.04.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
618 Péan N, Doignon I, Tordjmann T. Gut microbiota and bile acids: an old story revisited (again). Clin Res Hepatol Gastroenterol 2014;38:129-31. [PMID: 23916556 DOI: 10.1016/j.clinre.2013.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
619 Hliwa A, Ramos-Molina B, Laski D, Mika A, Sledzinski T. The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update. Int J Mol Sci 2021;22:6900. [PMID: 34199035 DOI: 10.3390/ijms22136900] [Reference Citation Analysis]
620 Capurso G, Lahner E. The interaction between smoking, alcohol and the gut microbiome. Best Pract Res Clin Gastroenterol. 2017;31:579-588. [PMID: 29195678 DOI: 10.1016/j.bpg.2017.10.006] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 19.5] [Reference Citation Analysis]
621 Grabherr F, Grander C, Effenberger M, Adolph TE, Tilg H. Gut Dysfunction and Non-alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne). 2019;10:611. [PMID: 31555219 DOI: 10.3389/fendo.2019.00611] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 14.0] [Reference Citation Analysis]
622 Puri P, Sanyal AJ. The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2018;22:121-32. [PMID: 29128052 DOI: 10.1016/j.cld.2017.08.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
623 Tretola M, Maghin F, Silacci P, Ampuero S, Bee G. Effect of Supplementing Hydrolysable Tannins to a Grower-Finisher Diet Containing Divergent PUFA Levels on Growth Performance, Boar Taint Levels in Back Fat and Intestinal Microbiota of Entire Males. Animals (Basel) 2019;9:E1063. [PMID: 31810259 DOI: 10.3390/ani9121063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
624 Reuter B, Bajaj JS. Microbiome: Emerging Concepts in Patients with Chronic Liver Disease.Clin Liver Dis. 2020;24:493-520. [PMID: 32620285 DOI: 10.1016/j.cld.2020.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
625 Zhu R, Baker SS, Moylan CA, Abdelmalek MF, Guy CD, Zamboni F, Wu D, Lin W, Liu W, Baker RD, Govindarajan S, Cao Z, Farci P, Diehl AM, Zhu L. Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers: Elevated alcohol-metabolizing genes in NAFLD. J Pathol 2016;238:531-42. [DOI: 10.1002/path.4650] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
626 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
627 Zhang YL, Cai LT, Qi JY, Lin YZ, Dai YC, Jiao N, Chen YL, Zheng L, Wang BB, Zhu LX, Tang ZP, Zhu RX. Gut microbiota contributes to the distinction between two traditional Chinese medicine syndromes of ulcerative colitis. World J Gastroenterol. 2019;25:3242-3255. [PMID: 31333315 DOI: 10.3748/wjg.v25.i25.3242] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
628 Mouzaki M, Bramlage K, Arce-Clachar AC, Xanthakos SA. Serum Immunoglobulin A Levels Do Not Correlate With Liver Disease Severity in Pediatric Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr 2018;67:631-4. [PMID: 30363043 DOI: 10.1097/MPG.0000000000002104] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
629 Munukka E, Pekkala S, Wiklund P, Rasool O, Borra R, Kong L, Ojanen X, Cheng SM, Roos C, Tuomela S, Alen M, Lahesmaa R, Cheng S. Gut-adipose tissue axis in hepatic fat accumulation in humans. Journal of Hepatology 2014;61:132-8. [DOI: 10.1016/j.jhep.2014.02.020] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
630 Demir M, Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Krawczyk M, Nowag A, Scholz CJ, Kretzschmar A, Roderburg C, Lammert F, Goeser T, Kasper P, Steffen HM. Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time? J Gastroenterol Hepatol 2020;35:1969-77. [PMID: 32267559 DOI: 10.1111/jgh.15071] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
631 Jiao N, Baker SS, Chapa-Rodriguez A, Liu W, Nugent CA, Tsompana M, Mastrandrea L, Buck MJ, Baker RD, Genco RJ, Zhu R, Zhu L. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2018;67:1881-1891. [PMID: 28774887 DOI: 10.1136/gutjnl-2017-314307] [Cited by in Crossref: 166] [Cited by in F6Publishing: 144] [Article Influence: 41.5] [Reference Citation Analysis]
632 Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther 2019;50:144-58. [PMID: 31149745 DOI: 10.1111/apt.15314] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
633 Konikoff T, Gophna U. Oscillospira: a Central, Enigmatic Component of the Human Gut Microbiota. Trends Microbiol 2016;24:523-4. [PMID: 26996766 DOI: 10.1016/j.tim.2016.02.015] [Cited by in Crossref: 202] [Cited by in F6Publishing: 177] [Article Influence: 40.4] [Reference Citation Analysis]
634 Wang W, Li Q, Chai W, Sun C, Zhang T, Zhao C, Yuan Y, Wang X, Liu H, Ye H. Lactobacillus paracasei Jlus66 extenuate oxidative stress and inflammation via regulation of intestinal flora in rats with non alcoholic fatty liver disease. Food Sci Nutr 2019;7:2636-46. [PMID: 31428351 DOI: 10.1002/fsn3.1118] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
635 Joshi D, Gupta N, Samyn M, Deheragoda M, Dobbels F, Heneghan MA. The management of childhood liver diseases in adulthood. Journal of Hepatology 2017;66:631-44. [DOI: 10.1016/j.jhep.2016.11.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
636 Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. Gut microbiota and metabolic syndrome. World J Gastroenterol. 2014;20:16079-16094. [PMID: 25473159 DOI: 10.3748/wjg.v20.i43.16079] [Cited by in CrossRef: 221] [Cited by in F6Publishing: 172] [Article Influence: 36.8] [Reference Citation Analysis]
637 Wegmann U, Louis P, Goesmann A, Henrissat B, Duncan SH, Flint HJ. Complete genome of a new Firmicutes species belonging to the dominant human colonic microbiota ('Ruminococcus bicirculans') reveals two chromosomes and a selective capacity to utilize plant glucans. Environ Microbiol 2014;16:2879-90. [PMID: 23919528 DOI: 10.1111/1462-2920.12217] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
638 Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut. 2018;67:380-388. [PMID: 29150490 DOI: 10.1136/gutjnl-2017-315068] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 20.5] [Reference Citation Analysis]
639 Wang Q, Lu Q, Shao W, Jiang Z, Hu H. Dysbiosis of gut microbiota after cholecystectomy is associated with non-alcoholic fatty liver disease in mice. FEBS Open Bio 2021. [PMID: 34184432 DOI: 10.1002/2211-5463.13243] [Reference Citation Analysis]
640 Azarang A, Farshad O, Ommati MM, Jamshidzadeh A, Heydari R, Abootalebi SN, Gholami A. Protective Role of Probiotic Supplements in Hepatic Steatosis: A Rat Model Study.Biomed Res Int. 2020;2020:5487659. [PMID: 33299871 DOI: 10.1155/2020/5487659] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
641 Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411-428. [PMID: 31028350 DOI: 10.1038/s41575-019-0145-7] [Cited by in Crossref: 268] [Cited by in F6Publishing: 233] [Article Influence: 134.0] [Reference Citation Analysis]
642 Mizukami T, Yokoyama A, Yokoyama T, Onuki S, Maruyama K. Screening by Total Colonoscopy Following Fecal Immunochemical Tests and Determinants of Colorectal Neoplasia in Japanese Men With Alcohol Dependence. Alcohol Alcohol 2017;52:131-7. [PMID: 28182201 DOI: 10.1093/alcalc/agw071] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
643 Meroni M, Longo M, Dongiovanni P. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients. 2019;11. [PMID: 31689910 DOI: 10.3390/nu11112642] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
644 Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology 2020;158:1881-98. [PMID: 32044317 DOI: 10.1053/j.gastro.2020.01.049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 25.0] [Reference Citation Analysis]
645 Norris GH, Blesso CN. Dietary sphingolipids: potential for management of dyslipidemia and nonalcoholic fatty liver disease. Nutr Rev 2017;75:274-85. [PMID: 28383715 DOI: 10.1093/nutrit/nux004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
646 Chakaroun RM, Massier L, Kovacs P. Gut Microbiome, Intestinal Permeability, and Tissue Bacteria in Metabolic Disease: Perpetrators or Bystanders? Nutrients 2020;12:E1082. [PMID: 32295104 DOI: 10.3390/nu12041082] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 44.0] [Reference Citation Analysis]
647 Mendel I, Yacov N, Shoham A, Ishai E, Breitbart E. Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis. Dig Dis Sci 2016;61:2545-53. [PMID: 27074921 DOI: 10.1007/s10620-016-4159-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
648 Nagashimada M, Honda M. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics. Int J Mol Sci 2021;22:8008. [PMID: 34360773 DOI: 10.3390/ijms22158008] [Reference Citation Analysis]
649 Chang C, Lin H. Dysbiosis in gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2016;30:3-15. [PMID: 27048892 DOI: 10.1016/j.bpg.2016.02.001] [Cited by in F6Publishing: 38] [Reference Citation Analysis]
650 Osborne G, Wu F, Yang L, Kelly D, Hu J, Li H, Jasmine F, Kibriya MG, Parvez F, Shaheen I, Sarwar G, Ahmed A, Eunus M, Islam T, Pei Z, Ahsan H, Chen Y. The association between gut microbiome and anthropometric measurements in Bangladesh. Gut Microbes 2020;11:63-76. [PMID: 31138061 DOI: 10.1080/19490976.2019.1614394] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
651 Goto M, Iohara D, Michihara A, Ifuku S, Azuma K, Kadowaki D, Maruyama T, Otagiri M, Hirayama F, Anraku M. Effects of surface-deacetylated chitin nanofibers on non-alcoholic steatohepatitis model rats and their gut microbiota. Int J Biol Macromol 2020;164:659-66. [PMID: 32698063 DOI: 10.1016/j.ijbiomac.2020.07.184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
652 Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease. Am J Physiol Gastrointest Liver Physiol 2020;318:G84-98. [PMID: 31657225 DOI: 10.1152/ajpgi.00118.2019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
653 Cho YE, Kim DK, Seo W, Gao B, Yoo SH, Song BJ. Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol-Inducible Cytochrome P450-2E1-Mediated Oxidative and Nitrative Stress. Hepatology 2021;73:2180-95. [PMID: 30959577 DOI: 10.1002/hep.30652] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 17.0] [Reference Citation Analysis]
654 Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17:481. [PMID: 27043550 DOI: 10.3390/ijms17040481] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 10.6] [Reference Citation Analysis]
655 Hrncir T, Hrncirova L, Kverka M, Tlaskalova-Hogenova H. The role of gut microbiota in intestinal and liver diseases. Lab Anim 2019;53:271-80. [PMID: 30580671 DOI: 10.1177/0023677218818605] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
656 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
657 Mukherjee R, Moreno-Fernandez ME, Giles DA, Cappelletti M, Stankiewicz TE, Chan CC, Divanovic S. Nicotinamide adenine dinucleotide phosphate (reduced) oxidase 2 modulates inflammatory vigor during nonalcoholic fatty liver disease progression in mice. Hepatol Commun 2018;2:546-60. [PMID: 29761170 DOI: 10.1002/hep4.1162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
658 Lucke A, Böhm J, Zebeli Q, Metzler-Zebeli BU. Dietary Deoxynivalenol Contamination and Oral Lipopolysaccharide Challenge Alters the Cecal Microbiota of Broiler Chickens. Front Microbiol 2018;9:804. [PMID: 29922239 DOI: 10.3389/fmicb.2018.00804] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
659 Lim MY, Rho M, Song YM, Lee K, Sung J, Ko G. Stability of gut enterotypes in Korean monozygotic twins and their association with biomarkers and diet. Sci Rep 2014;4:7348. [PMID: 25482875 DOI: 10.1038/srep07348] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 9.1] [Reference Citation Analysis]
660 Lee Y, Lee HY. Revisiting the Bacterial Phylum Composition in Metabolic Diseases Focused on Host Energy Metabolism. Diabetes Metab J. 2020;44:658-667. [PMID: 32662252 DOI: 10.4093/dmj.2019.0220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
661 Castaño-Rodríguez N, Mitchell HM, Kaakoush NO. NAFLD, Helicobacter species and the intestinal microbiome. Best Pract Res Clin Gastroenterol 2017;31:657-68. [PMID: 29566909 DOI: 10.1016/j.bpg.2017.09.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
662 Joshi-Barve S, Kirpich I, Cave MC, Marsano LS, McClain CJ. Alcoholic, Nonalcoholic, and Toxicant-Associated Steatohepatitis: Mechanistic Similarities and Differences. Cell Mol Gastroenterol Hepatol 2015;1:356-67. [PMID: 28210688 DOI: 10.1016/j.jcmgh.2015.05.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
663 Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. J Clin Exp Hepatol. 2015;5:147-158. [PMID: 26155043 DOI: 10.1016/j.jceh.2015.02.002] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 11.7] [Reference Citation Analysis]
664 Sun L, Ma L, Ma Y, Zhang F, Zhao C, Nie Y. Insights into the role of gut microbiota in obesity: Pathogenesis, mechanisms, and therapeutic perspectives. Protein Cell. 2018;9:397-403. [PMID: 29725936 DOI: 10.1007/s13238-018-0546-3] [Cited by in Crossref: 93] [Cited by in F6Publishing: 75] [Article Influence: 46.5] [Reference Citation Analysis]
665 Yeo YH, Lai YC. Redox Regulation of Metabolic Syndrome: Recent Developments in Skeletal Muscle Insulin Resistance and Non-alcoholic Fatty Liver Disease (NAFLD). Curr Opin Physiol 2019;9:79-86. [PMID: 32818162 DOI: 10.1016/j.cophys.2019.05.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
666 Arslan N. Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol. 2014;20:16452-16463. [PMID: 25469013 DOI: 10.3748/wjg.v20.i44.16452] [Cited by in CrossRef: 89] [Cited by in F6Publishing: 68] [Article Influence: 14.8] [Reference Citation Analysis]
667 Gutierrez Lopez DE, Lashinger LM, Weinstock GM, Bray MS. Circadian rhythms and the gut microbiome synchronize the host's metabolic response to diet. Cell Metab 2021;33:873-87. [PMID: 33789092 DOI: 10.1016/j.cmet.2021.03.015] [Reference Citation Analysis]
668 Lau E, Carvalho D, Freitas P. Gut Microbiota: Association with NAFLD and Metabolic Disturbances. Biomed Res Int. 2015;2015:979515. [PMID: 26090468 DOI: 10.1155/2015/979515] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]